

COLORECTAL CANCER DIAGNOSIS AND THERAPEUTIC UPDATES



Editors:
Sankha Bhattacharya
Amit Page
Saurabh Maru
Shilpa Dawre

Bentham Books

Colorectal Cancer Diagnosis and Therapeutic Updates

Edited by

Sankha Bhattacharya

*Department of Pharmaceutics
School of Pharmacy & Technology Management
SVKM'S NMIMS Deemed-to-be University
India*

Amit Page

*Department of Pharma Science
School of Pharmacy & Technology Management
SVKM'S NMIMS Deemed-to-be University
India*

Saurabh Maru

*Department of Pharmacology
School of Pharmacy & Technology Management
SVKM'S NMIMS Deemed-to-be University
India*

&

Shilpa Dawre

*Department of Pharmaceutics
School of Pharmacy & Technology Management
SVKM'S NMIMS Deemed-to-be University
India*

Colorectal Cancer Diagnosis and Therapeutic Updates

Editors: Sankha Bhattacharya, Amit Page, Saurabh Maru and Shilpa Dawre

ISBN (Online): 978-981-5040-94-4

ISBN (Print): 978-981-5040-95-1

ISBN (Paperback): 978-981-5040-96-8

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

| | |
|--|----|
| FOREWORD | i |
| PREFACE | ii |
| ACKNOWLEDGEMENT | iv |
| LIST OF CONTRIBUTORS | v |
| CHAPTER 1 COLORECTAL CANCER DIAGNOSIS | 1 |
| <i>Sankha Bhattacharya, Amit Page, Kapil Gore and Amaiyya Agrawal</i> | |
| INTRODUCTION | 1 |
| Invasive Examination | 2 |
| NON-INVASIVE DIAGNOSIS METHODS | 3 |
| Fecal Occult Blood Test | 3 |
| Non-enzymatic Tumor Markers | 4 |
| Lysosomal Exoglycosidases as Potential CRC Markers | 5 |
| CONCLUSION | 6 |
| CONSENT FOR PUBLICATION | 6 |
| CONFLICT OF INTEREST | 6 |
| ACKNOWLEDGEMENTS | 6 |
| REFERENCES | 6 |
| CHAPTER 2 SCREENING FOR COLORECTAL CARCINOMA | 8 |
| <i>Sankha Bhattacharya, Saurabh Maru and Aseem Setia</i> | |
| INTRODUCTION | 8 |
| DETECTION OF EARLY COLORECTAL CARCINOMA | 9 |
| EARLY DIAGNOSIS OF COLORECTAL CARCINOMA | 9 |
| WHAT IS SCREENING? | 9 |
| WHO SHOULD BE SCREENED? | 9 |
| SCREENING PEOPLE AT AN AVERAGE RISK FOR COLORECTAL CARCINOMA ... | 10 |
| Fecal Occult Blood Test | 10 |
| Flexible Sigmoidoscopy | 11 |
| Combination of FOBT and Flexible Sigmoidoscopy | 11 |
| Colonoscopy | 11 |
| SCREENING PEOPLE AT INCREASED RISK FOR COLORECTAL CARCINOMA | 12 |
| Genetic Syndromes | 12 |
| NEW SCREENING TESTS | 13 |
| CT Colonography | 13 |
| Faecal Occult Blood Test | 13 |
| CONCLUSION | 13 |
| CONSENT FOR PUBLICATION | 13 |
| CONFLICT OF INTEREST | 13 |
| ACKNOWLEDGEMENTS | 13 |
| REFERENCES | 14 |
| CHAPTER 3 HISTOPATHOLOGY | 16 |
| <i>Sankha Bhattacharya, Shilpa Dawre and Dyanesh Saindane</i> | |
| INTRODUCTION | 16 |
| NORMAL HISTOLOGY OF COLORECTAL AREA | 16 |
| GENERAL PRESENTATION IN COLORECTAL CANCER | 17 |
| NEED FOR HISTOPATHOLOGICAL INSPECTION IN COLORECTAL CARCINOMA | 18 |

| | |
|---|----|
| FACTORS INVOLVED IN THE HISTOPATHOLOGICAL ANALYSIS OF COLORECTAL CARCINOMA | 18 |
| HISTOPATHOLOGIC DIAGNOSIS OF COLORECTAL CANCER | 19 |
| HISTOLOGIC VARIANTS | 20 |
| GRADING OF COLORECTAL CARCINOMA USING HISTOPATHOLOGICAL ANALYSIS | 20 |
| Process of Grading the Cancers | 21 |
| <i>Issues with PDC System and their Rectification</i> | 22 |
| CONCLUSION | 22 |
| CONSENT FOR PUBLICATION | 22 |
| CONFLICT OF INTEREST | 22 |
| ACKNOWLEDGEMENTS | 22 |
| REFERENCES | 22 |
| CHAPTER 4 CHEMOTHERAPY AND COLORECTAL CANCER | 24 |
| <i>Kapil Gore, Dnyanesh Saindane and Sankha Bhattacharya</i> | |
| INTRODUCTION | 24 |
| CHEMOTHERAPY AND COLORECTAL CANCER | 24 |
| Administration of Chemotherapeutic Agents | 24 |
| CHEMOTHERAPY IN DIFFERENT STAGES OF COLORECTAL CANCER | 25 |
| COMPONENTS OF CHEMOTHERAPY | 26 |
| 5-Fluorouracil (5-FU) | 26 |
| Irinotecan | 27 |
| Oxaliplatin | 27 |
| NOVEL THERAPIES FOR COLORECTAL CARCINOMA | 27 |
| Agarose Microbeads | 27 |
| Anti-inflammatory Agents | 28 |
| Probiotics | 28 |
| Functional Foods | 28 |
| TARGETED THERAPIES | 29 |
| Targeting EGFR | 29 |
| Cetuximab and Panitumumab | 29 |
| BRAF Inhibitors | 30 |
| HER-2 Inhibitors | 30 |
| Targeting VEGF | 30 |
| Bevacizumab | 30 |
| Novel anti-VEGFR Agents | 31 |
| HGF/C-MET Pathway | 31 |
| HGF Inhibitors | 32 |
| MET Antagonists | 32 |
| TKIs | 32 |
| IMMUNE CHECKPOINT BLOCKADE | 32 |
| ADJUVANT AND NEOADJUVANT THERAPY USING TARGETED MEDICINE | 33 |
| CONCLUSION | 34 |
| CONSENT FOR PUBLICATION | 34 |
| CONFLICT OF INTEREST | 34 |
| ACKNOWLEDGEMENTS | 34 |
| REFERENCES | 34 |
| CHAPTER 5 ROBOTICS FOR RECTAL CANCER | 37 |
| <i>Dnyanesh Saindane, Ajay Madrewar and Sankha Bhattacharya</i> | |
| INTRODUCTION | 37 |

| | |
|--|----|
| TOTAL MESORECTAL EXCISION | 37 |
| Techniques Abdominoperineal Resection | 38 |
| Coloanal Anastomosis | 38 |
| LOCAL EXCISION | 38 |
| Transanal Excision | 38 |
| Transcoccygeal Excision | 39 |
| Transsphincteric Excision | 39 |
| Transanal Endoscopic Microsurgery | 39 |
| DISADVANTAGES OF SURGICAL TREATMENT FOR RECTAL CANCER | 40 |
| Short Term Effects of Surgery | 40 |
| Long Term Effects | 40 |
| LAPAROSCOPIC SURGERY | 40 |
| ADVANTAGES OVER CONVENTIONAL SURGICAL METHODS | 40 |
| Short Term Advantages Are: | 40 |
| Long Term Advantages | 41 |
| Limitations of Laparoscopic Surgery | 41 |
| ROBOTIC SURGERY FOR COLORECTAL CANCER | 42 |
| Components of the da Vinci surgical System | 42 |
| Operation of the System | 42 |
| OUTCOMES OF DA VINCI SURGICAL SYSTEM | 43 |
| Short Term Outcomes | 43 |
| Long Term Outcomes | 43 |
| CONCLUSION | 44 |
| CONSENT FOR PUBLICATION | 44 |
| CONFLICT OF INTEREST | 44 |
| ACKNOWLEDGEMENTS | 44 |
| REFERENCES | 44 |
| | |
| CHAPTER 6 LNCRNA NLIPMT INHIBITORS IN COLORECTAL CANCER | |
| MANAGEMENT | 46 |
| <i>Aseem Setia, Sankha Bhattacharya and Amaiyya Agrawal</i> | |
| INTRODUCTION | 46 |
| LNCRNA IN COLORECTAL CANCER | 49 |
| HOTAIR | 50 |
| H19 | 52 |
| MALAT 1 | 54 |
| INVOLVEMENT OF LNCRNAS IN CRC PATHOGENESIS | 55 |
| Wnt/ β -Catenin Pathway | 56 |
| EGFR/IGF-IR SIGNALING (PI3K AND KRAS PATHWAYS) | 59 |
| TGF-B SIGNALING PATHWAY | 60 |
| P53. PATHWAY | 60 |
| EMT PROGRAM | 61 |
| DETAIL DISCUSSION OF EXPERIMENTAL DATA CONDUCTED FOR | |
| COLORECTAL CANCER (CRC) | 61 |
| lncRNA Overexpression TGF- β 1 Downregulation by NLIPMT Inhibits Colorectal Cancer | |
| Cell Migration and Invasion | 61 |
| The Activation of KPNA3 by LncRNA DLEU1 Leads to the Advancement of Colorectal | |
| Cancer | 62 |
| CONCLUSION | 63 |
| ABBREVIATIONS | 63 |
| CONSENT FOR PUBLICATION | 64 |

| | |
|---|-----------|
| CONFLICT OF INTEREST | 64 |
| ACKNOWLEDGEMENTS | 64 |
| REFERENCES | 64 |
| CHAPTER 7 PATHWAYS IN COLORECTAL CANCER | 71 |
| <i>Ajay Madrewar, Kapil Gore and Sankha Bhattacharya</i> | |
| INTRODUCTION | 71 |
| CHROMOSOMAL INSTABILITY PATHWAY | 71 |
| Adenomatous Polyposis Coli gene and wnt Signaling Pathway | 72 |
| TP-53 Mutation | 72 |
| 18q Loss of Heterozygosity (LOH) | 72 |
| MICROSATELLITE INSTABILITY PATHWAY | 73 |
| EPIGENETIC INSTABILITY AND CPG METHYLATION | 73 |
| PI3K/AKT PATHWAY, PTEN, AND TGFBR2 | 74 |
| SIGNALLING PATHWAYS IN COLORECTAL CANCER | 75 |
| EGFR/MAPK Signaling Pathway | 75 |
| Notch Signaling Pathway | 75 |
| PI3K Signaling Pathway | 76 |
| TGF- β signalling Pathway | 77 |
| Wnt Pathway | 78 |
| CONCLUSION | 79 |
| CONSENT FOR PUBLICATION | 79 |
| CONFLICT OF INTEREST | 79 |
| ACKNOWLEDGEMENTS | 79 |
| REFERENCES | 79 |
| CHAPTER 8 RADIOTHERAPY IN COLORECTAL CANCER | 81 |
| <i>Amit Page, Dnyanesh Saindane and Sankha Bhattacharya</i> | |
| INTRODUCTION | 81 |
| TYPES OF RADIATION THERAPY | 82 |
| CLINICAL TRIALS OR RESEARCH STUDIES OF RADIATION AND CHEMO- RADIATION THERAPY IN COLORECTAL CANCER | 83 |
| Neoadjuvant Radiation Therapy | 86 |
| Probable Side Effects of Radiotherapy | 86 |
| CONCLUSION | 87 |
| CONSENT FOR PUBLICATION | 87 |
| CONFLICT OF INTEREST | 87 |
| ACKNOWLEDGEMENTS | 87 |
| REFERENCES | 87 |
| CHAPTER 9 SURVEILLANCE FOR COLORECTAL CANCER | 90 |
| <i>Saurabh Maru, Kapil Gore and Sankha Bhattacharya</i> | |
| INTRODUCTION | 90 |
| COLONOSCOPY | 91 |
| FLEXIBLE SIGMOIDOSCOPY | 92 |
| CONCLUSIONS | 93 |
| CONSENT FOR PUBLICATION | 93 |
| CONFLICT OF INTEREST | 93 |
| ACKNOWLEDGEMENTS | 93 |
| REFERENCES | 93 |
| CHAPTER 10 RECENT THERANOSTICS IN TREATMENT OF COLORECTAL CANCER | 95 |
| <i>Shilpa Dawre, Ajay Madrewar and Sankha Bhattacharya</i> | |

| | |
|--|-----|
| INTRODUCTION | 95 |
| NANOFLATFOMS FOR DRUG DELIVERY AND THERANOSTICS | 96 |
| NANOLIPOSOMAL BASED THERANOSTIC NANOPARTICLES | 97 |
| Prodrug Approach | 98 |
| SUPER MAGNETIC IRON-OXIDE NANOPARTICLES (SPIONS) | 99 |
| CONCLUSION | 100 |
| CONSENT FOR PUBLICATION | 100 |
| CONFLICT OF INTEREST | 100 |
| ACKNOWLEDGEMENTS | 101 |
| REFERENCES | 101 |
| CHAPTER 11 MANAGEMENT OF COLORECTAL CANCER | 103 |
| <i>Sankha Bhattacharya, Amit Page, Saurabh Maru and Shilpa Dawre</i> | |
| MANAGEMENT OF COLORECTAL CANCER | 103 |
| HOW CAN YOU PREPARE PATIENTS FOR SURGERY? | 104 |
| Enhanced Recovery After Surgery (ERAS) | 104 |
| Stomal Therapy | 104 |
| Bowel Preparation | 104 |
| Nutritional Interventions | 105 |
| LOCAL RECTAL TREATMENT OF RECTAL CANCER (CLINICS IN THE COLON A RECTAL) | 105 |
| Tumor Evaluation | 105 |
| Electrocoagulation | 106 |
| Contract Radiotherapy | 107 |
| Local Excision | 107 |
| ENDOSCOPIC TREATMENT | 108 |
| Snare Polypectomy | 108 |
| Endoscopic Mucosal Resection (EMR) | 108 |
| Endoscopic Submucosal Dissection | 109 |
| WHAT IS THE SURGICAL OPTION FOR COLORECTAL CANCER? | 109 |
| Open Surgery | 109 |
| Laparoscopic Surgery | 110 |
| WHAT ARE POSSIBLE COMPLICATIONS? | 110 |
| Immediate | 110 |
| Long Term | 110 |
| WHAT IS THE ROLE OF ADJUVANT CHEMOTHERAPY IN COLORECTAL CANCER TREATMENT? | 111 |
| CONCLUSION | 111 |
| CONSENT FOR PUBLICATION | 112 |
| CONFLICT OF INTEREST | 112 |
| ACKNOWLEDGEMENTS | 112 |
| REFERENCES | 112 |
| SUBJECT INDEX | 115 |

FOREWORD

Given the gap in the comprehensive book on “*Colorectal cancer diagnosis and therapeutic updates, and the new findings*”, the writers agreed to discuss as many key issues regarding colorectal cancer, its management, and therapeutic progress as necessary. This book is also unique in that it contains new information about lncRNA NLIPMT inhibitors and therapeutic use in the treatment of colorectal cancer. Another reason is the presence of several detailed chapters as well as a large number of appropriate illustrations. It is anticipated that after reading this book, the reader would have acquired the requisite skills for colorectal cancer diagnosis and clinical management. Knowing the signalling mechanisms involved in colorectal cancer targeting will open up fresh possibilities for cancer study in the reader's mind. Researchers and readers interested in finding a cure for colorectal cancer can read this book, according to the authors. The authors, in my view, will be fortunate to have grateful readers who obtain extensive expertise for their current practise in colorectal cancer treatment and therapeutics, as well as for future research.

Vineet Kumar Rai

Department of Pharmaceutics
ISF College of Pharmacy, Moga
Punjab
India

PREFACE

Cancer is a disease in which cells develop abnormally and may involve any part of the body. Cancer is distinguished by the sudden development of irregular cells. It spreads to other areas of the body and eventually to other organs; this is referred to as metastasizing. The most common cause of cancer-related death is metastasis. According to a World Health Organization (WHO) survey, about 9.6 million deaths were reported worldwide in 2018, and 7.6 million deaths were estimated in 2008 due to cancer. Lung, breast, colorectal, stomach, and liver cancers are some of the more prevalent cancers diagnosed in men. Breast cancer, colorectal cancer, lung cancer, cervical cancer, and thyroid cancer are some of the more prevalent cancers among women. Changing one's lifestyle and adopting more sustainable habits could prevent about 30 percent of cancer deaths. According to a study released on September 12, 2018 in "A Cancer Journal for Clinicians" by the International Agency for Research on Cancer (IARC), the top three cancer forms are prostate, female breast, and colorectal cancer, both of which are mainly present in humans. Colorectal cancer is the third most commonly diagnosed cancer (1.8 million patients, or 10.2 percent of all cases), followed by prostate cancer (1.3 million cases, or 7.1 percent), and stomach cancer (the fifth most commonly diagnosed cancer) (1.0 million cases, 5.7 percent). Per year, it is projected that 1.2 million people are diagnosed with colorectal cancer.

Colorectal cancer (CRC) is a complex disorder caused by the interaction of hereditary and environmental causes, which can be classified according to the importance of each of these factors. CRCs are often seasonal (70-80%), with age being the most important risk factor; hereditary variants account for just a small percentage of incidents. Colorectal cancer develops as a result of the accumulation of hereditary and epigenetic modifications. The most advanced CRCs grow from adenomas (adenoma-carcinoma sequence). The neoplastic transfer cycle is estimated to be about 10-15 years, which refers to the amount of time required to detect and remove these adenomas before they progress to invasive carcinoma. The three main carcinogenesis pathways for colorectal cancer (CRC) are currently being debated.

This book reflects on the most basic clinical and medical methods for colorectal cancer care. Furthermore, we concentrate on recent advancements in colorectal cancer science as well as the critical mechanisms involved in colorectal cancer treatment.

The chapters of this book are structured in such a manner that even readers with no prior awareness of the topic will learn about it in the book. As a result, the book's contents have been divided into eleven chapters.

We did our best to include relevant knowledge in a clear and concise manner. We hope that by the end of the book, readers will be able to follow other researchers in their pursuit of the topic's estimated supremacy. Furthermore, we hope to be able to contribute to the development of research in this area.

Sankha Bhattacharya

Associate Professor, Department of Pharmaceutics,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

Amit Page

Assistant Professor, Department of Pharma Science,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

Saurabh Maru

Assistant Professor, Department of Pharmacology,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

&

Shilpa Dawre

Assistant Professor, Department of Pharmaceutics,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

ACKNOWLEDGEMENT

We would like to convey our heartfelt appreciation to God Almighty for always being gracious and supportive to us. He offered us the chance to thrive and immerse ourselves in His unique molecular universe, which are gifts that only a few humans have seen. We humbly express our gratitude to our families for their patience and generosity throughout the writing of this novel. We would like to extend our heartfelt thanks to all those people who helped us along the way. This book is for those who want to expand their expertise in the area of cancer and keep themselves up to date.

Sankha Bhattacharya

Associate Professor, Department of Pharmaceutics,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

Amit Page

Assistant Professor, Department of Pharma Science,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

Saurabh Maru

Assistant Professor, Department of Pharmacology,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

&

Shilpa Dawre

Assistant Professor, Department of Pharmaceutics,
School of Pharmacy & Technology Management,
SVKM'S NMIMS Deemed-to-be University,
Shirpur, Maharashtra,
India

List of Contributors

| | |
|--------------------------------|---|
| Ajay Madrewar | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Amaiyya Agrawal | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Amit Page | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Aseem Setia | Department of Pharmaceutics, ISF College of Pharmacy GT Road (NH-95), Ghal Kalan, Moga, Punjab 142001, India |
| Dnyanesh Saindane | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Kapil Gore | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Sankha Bhattacharya | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Saurabh Maru | Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |
| Shilpa Dawre | Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India |

CHAPTER 1**Colorectal Cancer Diagnosis****Sankha Bhattacharya^{1,*}, Amit Page^{1,*}, Kapil Gore^{1,*} and Amaiyya Agrawal^{1,*}**¹ *Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India*

Abstract: A diagnosis is an important tool in the detection and combat of colorectal cancer. Early-diagnosed cancer can be cured easily. There are many invasive as well as non-invasive methods of diagnosis for colorectal cancer. Non-invasive methods usually involve the use of various biomarkers for diagnostic purposes. Recently, enzymes from lysosomes that take part in metastases have been discovered to have importance as a diagnostic tool.

Keywords: Biomarkers, Diagnosis, Invasive, Lysosomal exoglycosides, Non-invasive.

INTRODUCTION

Colorectal cancer is the third leading cause of death from cancer. It is observed that almost 4.3% of men and 4.0% of women in this world is susceptible to have colorectal cancer in upcoming times. The outcome for people with colorectal cancer is improving, but the overall five-year survival rates are still lower than 60%. There is a need for greater accuracy in diagnosis and staging. The astonishing fact about colorectal cancer (CRC) is that among all the colorectal cases, almost half the percentage is reported from developing countries. This might be due to the limited resources for diagnosis and poor health infrastructure, which ultimately leads to increased mortality rates due to CRC. Though, in western countries, the good health infrastructure and early screening and diagnosis improvise CRC treatment. As far as India is concerned, the age standard rate (ASR) for CRC cases is low, approximately 7.2 per 100,000 male population and 5.1 per 100,000 female population; yet India is a nation of 1.38 billion-plus people, with a staggering number of CRC-affected populations, and with a low five-year survival rate (less than 40%) [1].

* **Corresponding author Sankha Bhattacharya:** Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

Certain epigenetic disorders and genetic alterations can hinder CRC treatment. The basic reason for CRC is the methylation and covalent modification of histones. To make treatment of CRC more effective, early diagnosis of neoplasms and identification of pre-cancerous stages is essential [2]. It has been observed from histological data that CRC can cause perforation within the intestine; therefore, chances of obstructive ileus formation are pragmatic. Most of the patients, who witnessed colonic polyps at early stages, ultimately develop CRC. It is of utmost importance to remove adenomatous polyps to prevent the conversion of CRC from colonic polyps (Fig. (1) [3].




Fig. (1). (A) Developmental process of nonpolypoid colorectal neoplasms; (B). Macroscopic classification of colorectal neoplasms; (C). Submucosal invasion.

Invasive Examination

To identify the CRC, the most common practice is rectal examination. During the examination, almost around 70% rectal and 30% CRCs can be diagnosed. But it is most important to have the necessary experience as a physician who handles the case. Endoscopy is the most prominent tool or method to instantly recognize CRC.

To perform the histological examination and to perfectly identify and localize tumors associated with CRC, it is important to perform sigmoidoscopy and colonoscopy, which are a type of endoscopy [4]. With the help of recent

advancements in endoscopy, it is possible to detect tumors with up to 92-97% accuracy. If there is an advancement of CRC to lower parts of the colon, then sigmoidoscopy can play a pivotal role in diagnosing the condition, whereas colonoscopy helps to inspect the entire colon with the proper illustration of sensitive information. During the diagnosis of CRC, the colonoscopy was found to have many advantages, *viz.*, it can increase the accuracy of detection with a limited time frame. To perform the palliative procedure and CRC diagnosis sigmoidoscopy would be a necessary tool. For those patients, who are at potential risk if the surgical operation is performed, sigmoidoscopy can help to clean and identify obstructions generated due to CRC. The biggest disadvantage of sigmoidoscopy is its invasive operations, which can create certain discomfort to the patients; as it may create preformation and bleeding in the intestine [5]. Lead to circumvent such problems, recently developed virtual colonoscopy created a buzz within the scientific community. By applying computer tomography, it is possible to obtain 3D images of the large intestine. Most importantly, the non-invasive virtual colonoscopy helps to decrease the risk of unnecessary bleeding from the intestine [6]. Many imaging tests like nuclear magnetic resonance (NMR), endorectal ultrasonography (USG) help to identify the actual conditions of CRC when the patient has severe focal lesions. From the biomedical research, it was found that, alternation of carbohydrate, fluor-18-fluorodeoxyglucose positron could be the reason for CRC. The positron emission computed tomography (18F-FDG PET/CT) depicts a prognostic value with response to the treatment. The 18F-FDG PET/CT tomography helps to identify the potential chemotherapeutic challenges in patients, who are affected with CRC. From the ongoing research, it was observed that 18F-FDG-PET/CT has a significant amount of CT sensitivity; which allows researchers to identify cancer metastases within the liver. Many pieces of research suggest that positron emission tomography (FDG PET) was found to be the most potent tool to identify the interpreted results from gastrointestinal stromal tumours. The treatment using 18F-FDG-PET/CT has shown positive responses within 10 days of the initialization of treatment. This technique is more effective in patients after radio-chemotherapy. As per the NICE guidelines 27, if the body persists lesion, colonoscopy is recommended.

NON-INVASIVE DIAGNOSIS METHODS

Fecal Occult Blood Test

In this technique, the hemoglobin content was identified in human fecal. If traces of hemoglobin are found, it indicates that the blood might be shedding from polyps (1-2cm) or CRC. This test needs to be repeated several times to enhance sensitivity up to 90%. In CRC diagnosis, the scientist is concerned about the

Screening for Colorectal Carcinoma

Sankha Bhattacharya^{1,*}, Saurabh Maru^{1,*} and Aseem Setia^{2,*}

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

² Research Scholar, Department of Pharmaceutics, ISF College of Pharmacy GT Road (NH-95), Ghal Kalan, Moga, Punjab 142001, India

Abstract: Colorectal carcinoma is the fourth most commonly diagnosed malignancy. As it is hidden in many cases and as the onset is undetectable, it may prove to be fatal. Hence, early screening colorectal cancer is a way to prevent this disease. Screening depends upon various factors, such as familial history, history of the disease, or any condition which could lead to colorectal carcinoma. Various tests, such as fecal occult blood test, sigmoidoscopy, and CT scan, are available for screening. The screening method to be used depends upon various contributing factors. Screening can be invasive or can be non-invasive using many markers.

Keywords: Detection, Early diagnosis, Novel tests, Screening tests.

INTRODUCTION

Colorectal carcinoma, the fourth most common internal cancer, is a common internal malignancy. In Canada, around 24,800 new cases of colorectal carcinoma were reported in 2021, and 9600 deaths of affected individuals. The disease occurrence per year has increased in men and women since 1988. In terms of the benefits of detecting colorectal carcinoma, population-based screening is gaining popularity around the world. In January 2007, Colon Cancer Check was introduced by the Ontario Ministry of Health and Long-Term Care and Cancer Care Ontario in a collaborative approach. The probability of having this cancer at birth is 7.4% in men and 6.5% in women, while the probability of dying with this cancer is 3.7% in men and 3.3% in women [1].

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

DETECTION OF EARLY COLORECTAL CARCINOMA

The survival of the patient depends on the stage of CRC at which they have been diagnosed. In England, The National Bowel Cancer Screening Programme showed a reduction of colorectal cancer in the early stage detected group than the control group. This helped in understanding that the early-stage detection of the disease could help in the prevention of most colorectal carcinoma [2]. Several colorectal carcinomas do not show any symptoms until a stage where a certain obstruction might result in altered regular bowel habits and may cause abdominal discomfort. Blood in the stool can be seen at the early stage of colon and rectal carcinoma, which is frequent and unpredictable. The disease starts with a crypt and with the progression of gene mutations, further giving rise to small polyp, which then sooner or later metastasizes. This natural process provides a window of time for detection as early as possible and then removing the polyps. With an early-stage detection of carcinoma, the deaths and disease can be reduced drastically [3].

EARLY DIAGNOSIS OF COLORECTAL CARCINOMA

The need for colorectal cancer screening is urgent and widespread and serious, as it was the second leading cause of death in Canada, affecting both men and women equally. Early detection of carcinoma was possible with some screening tests with high accuracy. The early-stage removal of adenomatous polyps helped in the reduction of incidences and also reduced mortality due to colorectal carcinoma. The advantages of early screening compensate for its problems.

Significant efforts are needed from patients, medical practitioners, and government. As in Canada, the low percentage of detection was contrasted with the indicative presentation [4].

WHAT IS SCREENING?

Screening is the identification of potential patients who might likely have colorectal carcinoma or adenomatous polyps without showing any indications or signs. Reducing the mortality rate is the main reason for screening [5].

WHO SHOULD BE SCREENED?

New cases could be seen without any affecting factor for colorectal carcinoma. Occurrence is about 75%. People without any factors are at very low risk compared to the ones who have any family history of colorectal carcinoma, which is about 15 -20%. Hereditary nonpolyposis colon cancer accounts for 4–7% of the total cases, and familial adenomatous polyposis accounting for the remaining 1%.

The remaining 1% consists of a variety of unusual disease situations like Crohn's colitis, Peutz-Jeghers syndrome, chronic ulcerative colitis, and familial polyposis. Various factors that could be kept in mind are low fiber and high saturated fat diet, older age, inactive routine, and extreme consumption of alcohol [6].

Depending on the risk of colorectal cancer the screening is different. With some questions asked, the risk can be defined well for colorectal cancer:

- a. Have you ever suffered an adenomatous polyp or colorectal cancer?
- b. Is there any history or current medical condition of diseases such as inflammatory bowel disease that could lead to or influence colorectal cancer?
- c. Is there a family history of adenomatous polyps or colorectal carcinoma? If yes, then how many members of the family are related to the patient, and at what age was the first polyp detected [7]?

SCREENING PEOPLE AT AN AVERAGE RISK FOR COLORECTAL CARCINOMA

Screening need to be offered to average-risked men and women. Use of fecal occult blood test, colonoscopy, or sigmoidoscopy in adults of age 50 - 75 year is suggested by the U.S. Preventive Services Task Force. Due to a lack of evidence, positive or negative effects of fecal DNA testing and computed tomography colonography as screening modalities for colorectal cancer are not known. Due to the presence of options, patients may choose screening techniques depending on their preferences [8].

Fecal Occult Blood Test

This involves tests based on dietary restriction. Guaiac-based test that has dietary restrictions or the immunochemical test, which has no dietary restriction. Within three consecutive stools, two would be taken for examination without rehydration. Colonoscopy is suggested for patients who might get the test positive. The FOBT screening test has helped reduce the mortality rate in Minnesota trials by 21%. A review of three clinical studies found that a restricted diet cannot reduce the positivity rate in older people and that a very strict diet may reduce compliance and reduce sensitivity to the guaiac-based test [9]. A major drawback of this test is that it cannot detect some carcinoma and polyps. False test results could have been seen for colorectal neoplasia, and due to this, the patient might need to go through cost, risk, and discomfort of colonoscopy without much advantage [10].

Histopathology

Sankha Bhattacharya^{1,*}, Shilpa Dawre^{1,*} and Dyanesh Saindane^{1,*}

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Histopathology involves the study of tissue samples using a microscope to understand the normal and abnormal contents of a given sample. Normal histology of colorectal areas, such as mucosa and muscular, is greatly altered during the development of cancer. Colorectal cancer can be divided into various grades during the histopathological examination of tissues, which shows the extent of invasion of tumour into the colon. This examination can also be used to understand the type of carcinoma in the colon. Many factors affect this histopathological study and many drawbacks can occur in grading systems that need to be improved.

Keywords: Alterations, Grading, Histopathology, Normal histology, Variant.

INTRODUCTION

Histopathology involves scanning of tissue samples under the microscope to investigate and understand the presentation of disease at a cellular level. It allows us to understand any cellular abnormality which occurs in the disease. This feature can be used to identify the grade of cancer, showing the extent of growth/spread of cancer. The variant of cancer has its characteristic appearance in a microscopic examination which can be easily identified and treated accordingly. Grading can be done by various methods, however, they have their drawbacks.

NORMAL HISTOLOGY OF COLORECTAL AREA

The colon has a mucosa made of columnar epithelium. It shows the presence of a brush border. Many goblet cells secreting mucus are present in this layer. Lamina propria is rich in leukocytes and lymphoid nodules buried into the lower layer. Muscularis mucosae are prominent and can be divided into an inner circular layer and outer layer arranged lengthwise. The submucosa is a mixture of irregular con-

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

nective and adipose tissue. It contains many blood vessels and neurons. Muscularis externa is made up of thick bands of muscles running along the length of the colon [1].

The rectal region shows histology more or less similar to the colon. Classic features, such as teniae coli and haustra, are absent in the rectal region. The muscular layer is well-developed, which helps in contraction during defecation [2].

GENERAL PRESENTATION IN COLORECTAL CANCER

In the first stage (stage 0) of colorectal cancer, dysplasia of epithelium of the colorectal area causes abnormal growth, leading to the formation of a mass of cells or polyps. Due to genetic abnormalities, the cells in polyps now divide uncontrollably to form neoplasia. These neoplastic tumors are localized to the epithelium or endothelium. They do not exhibit potential for metastasis.

The extensive dysplasia in the localized tumour is associated with some rather distinguishable changes in cell structure and architecture. Changes in architecture can be as remarkable as seeing glandular epithelial cells in the muscularis of the colon. Cells and nuclei can be seen in more than one distinct shape. The amount of chromosomal material in the nucleus is more than normal. The polarity of a nucleus is disturbed due to cytoskeletal disturbances. The nuclei may exhibit crowding. Cells, due to genetic abnormalities, lose their glandular structure. The nuclear matter is in excess and can be seen arranged irregularly.

High-grade dysplasia in polyps is also accompanied by many changes in the cellular structure. The cells in the polyp may lose their glandular nature; the mucin production may stop permanently; the nuclear matter is in a higher amount as compared to cytoplasm; the appearance of nuclei also changes; and The cells may appear irregularly arranged in cribriform shape.

In the second stage (stage 1), cancer spreads to the layer below the mucous membrane, *i.e.*, to the submucosa. This certifies the polyp being cancerous. This tumour now has the ability to enter deeper into the layers of the intestine and invade the vasculature of the body [3].

In further stages, the polyp invades deeper into layers of the colon, finally crossing muscularis mucosae to enter the lymph nodes through which it can travel to other organs.

NEED FOR HISTOPATHOLOGICAL INSPECTION IN COLORECTAL CARCINOMA

1. Histological variants- there are many variations that can be seen in manifestations of colorectal carcinoma, such as mucinous adenocarcinoma, signet ring adenocarcinoma. These have different histologic features which can be diagnosed through histopathological studies. These help to identify variants, such as medullary carcinoma involving sheets of cells with a round nucleus with growth along the circumference of the tumour [4].
2. Cancer staging- earlier staging of colorectal carcinoma is based on gland formation in the tumour. But this analysis is not accurate due to high variability in individuals regarding gland formation. And the behavior of tumours, whether differentiated or not, is not very much different. Hence, a new criterion for dividing tumours into stages based on poorly differentiated clusters (PDC) is employed where the number of PDC is used to differentiate cancer into stages where the greater number of PDC means more advanced stage [5].
3. Prognosis- histopathological analysis can help to predict any future manifestations of colorectal carcinoma. Histopathologic analysis can reveal many parameters of the tumors, such as the variant, tumour stage, and invasion depth [4].

FACTORS INVOLVED IN THE HISTOPATHOLOGICAL ANALYSIS OF COLORECTAL CARCINOMA

1. Tumour grading- tumour grading is an important method for the prediction of prognosis and identification of tumours. But there is more than one way of grading the tumours, and they are not similar at all.
2. Nuclear grading- it involves analysis of size and shape of nucleus of dividing cells and implies that lower grade cancers do have very few numbers of such cells.
3. Tumour budding- it involves the formation of undifferentiated cells near the invasive edge of the tumor. The extent of budding affects the probability of recurrence even after the treatment. These ‘buds’ are very small in size and do not have any special function, such as secretion of mucin. Hence, distinguishing these buds from colorectal carcinoma is pretty difficult.
4. Tumour border architecture- it can be either smooth or rough. It does not indicate any staging of the tumour, but itself is an indication of worsening the condition of malignancy. Budding is observed more frequently in tumours with an irregular border [6].

Chemotherapy and Colorectal Cancer

Kapil Gore^{1,*}, Dnyanesh Saindane^{1,*} and Sankha Bhattacharya^{1,*}

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Chemotherapy is one of the established first-line options for the treatment of colorectal cancer. Chemotherapy contains various molecules acting against multiple factors, contributing to the growth of cancer cells. Chemotherapeutic regimens can vary based on the stages of cancer and the components as well as the strength of medications. The recent addition of agents such as antibodies against various molecular targets involved, such as receptors and components of signaling pathways, resulted in even more precise therapy.

Keywords: Chemotherapy, Components, Novel agents, Stages of cancer, Targeted therapies.

INTRODUCTION

Chemotherapy is the use of chemical moieties to treat cancer. Chemotherapy can be given systemically as well as locally. Chemotherapy regimens change based upon the cancer stage and include components having varied mechanisms of action. Their combinations show a synergistic effect in killing the cancer cells.

CHEMOTHERAPY AND COLORECTAL CANCER

Chemotherapy involves the treatment of colorectal cancer using medications that are taken orally or through an I.V. The drugs travel throughout the body and reach the desired tumour site, where they show their effect and kill the cancer cells [1].

Administration of Chemotherapeutic Agents

Systemic chemotherapy involves the entry of drugs and delivery through the bloodstream to reach the position of cancer in the colon or rectum. The drugs

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

involved in systemic chemotherapy are fluorouracil, capecitabine, irinotecan, oxaliplatin, trifluridine, and tripiracil (American Cancer Society) [1].

Regional chemotherapy: This type of therapy is carried out for metastatic cancers which may have spread to the liver. The hepatic artery, the most anticipated route of metastasis, is targeted. The artery is blocked to cut blood supply to the liver. Then drugs are injected, which enter the liver and show their effect limited to the liver only [2].

CHEMOTHERAPY IN DIFFERENT STAGES OF COLORECTAL CANCER

Chemotherapy is administered based on the stage of cancer, which describe its severity and progress. It is divided into stages 0 to 4 depending on the severity and progress. Stage 0 cancer is limited to layers of the colon and rectum. Surgery to remove the cancer is the most frequently sought option to get rid of cancer. Surgery includes the removal of a locally formed polyp or tumor. But in the case of large tumours, the area of the colon should be removed. Stage 1 cancer invades deeply in the colon but not outside of it. If the cancer is a part of polyp, it can be removed, and no cells are present at the edge. If the polyp is high grade, deeper surgical intervention is required. For cancer not in a polyp, the colon section must be severed [3].

Stage 2 cancers can be classified according to the level of invasion into their surroundings. 2A stage involves cancer reaching to tissues around the colon. 2B cancers reach as deep as the peritoneum and 2C cancers cross the peritoneum and reach even other organs. For this type of cancer, surgery for the removal of a specific part of the colon is the main method and adjuvant chemotherapy is also used to shrink the tumors. National comprehensive cancer network (NCCN) gives guidelines that vary upon high-risk factors, poorly differentiated clusters, invasion in lymph and other organs. For the 2A stage, treatment with 5-fluorouracil, leucovorin, or capecitabine is suggested. For those who exhibit high-risk factors in stage 2A or have progressed to stages 2B and 2C, treatment includes a combination of 5-fluorouracil & leucovorin, capecitabine, or a combination of 5-fluorouracil, leucovorin, capecitabine or therapy, including 5-fluorouracil, leucovorin, oxaliplatin, or a combination of oxaliplatin & capecitabine. In this treatment, the risk and benefit should always be considered [4].

Stage 3 cancers completely cross various layers of the colon and may invade nearby tissues by reaching nearby lymph nodes. Surgery is still the first option, and adjuvant chemotherapy is given to shrink the tumour. The chemotherapeutic regimen should start after a duration of 8 weeks from surgery and should last 5-6 months after surgery. The first-ever combination given was 5-fluorouracil and L-

folinic acid daily for 5 days in a month. After the addition of capecitabine in this regimen, the new combination showed a better effect and tolerance than the earlier combination. The addition of oxiplatin to 5-fluorouracil, folinic acid, and capecitabine enhanced the overall as well as the disease-free survival rate above 70% as compared to only fluoropyrimidine. Combinations such as FOLFIRI (folinic acid, fluorouracil, irinotecan), IFL(irinotecan & fluorouracil), and FOLFOX (Fluorouracil, oxaliplatin & folinic acid) are used in metastatic cancers, but these combined with VEGF/EGFR targeted therapies did not show any significant effect. The validated regimen for stage 3 includes combinations such as FOLFOX and CAPOX as a doublet regimen and combinations such as LV5FU2 (leucovorin & 5-fluorouracil) and capecitabine without oxaliplatin. CAPOX is superior to FOLFOX, where the number of injections is less. Dipyrimidine dehydrogenase deficiency should be considered before any treatment to avoid the toxicity of capecitabine (Adjuvant Chemotherapy for Stage III Colon Cancer, Julien Taieb 1,2,* and Claire Gallois 1,2).

Stage 4 cancers involve the spread of cancer to distant tissues. Chemotherapy is the major treatment option to control the spread of cancer. Surgery is not always preferred but can be considered for patients showing metastasis. 5-fluorouracil was the most preferred single-molecule for the treatment of progression of colorectal carcinoma. The addition of leucovorin as a biomodulator enhances the response and this combination is the best choice for patients intolerant for chemotherapy. Mayo and Rosewell park regimens of this combination are widely used. This combination shows better response and progress-free survival. Capecitabine, a fluorouracil prodrug can also be used along with leucovorin which reduces the toxicity even further.

Irinotecan is used solely when the above combination fails and has been shown to prolong survival by 2-3 months. In combination with 5-fluorouracil and leucovorin, it showed an even greater survival benefit. Irinotecan given along with i.v. bolus fluorouracil improved the survival time to 17-20 months. When combined with capecitabine, it showed increased toxicity; hence, it is not applied anymore. Oxiplatin, when used alone, has shown limited efficacy. When it is coupled with fluorouracil, leucovorin as a FOLFOX combination shows a much greater benefit. Along with capecitabine as a CAPOX combination, it can be used as first as well second-line therapy [5].

COMPONENTS OF CHEMOTHERAPY

5-Fluorouracil (5-FU)

5-FU is commonly used in patients with advanced-stage colorectal carcinoma. It is a member of the fluoropyrimidine class. This molecule incorporate itself into

CHAPTER 5

Robotics for Rectal Cancer**Dnyanesh Saindane¹, Ajay Madrewar¹ and Sankha Bhattacharya^{1,*}**¹ *Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India*

Abstract: Surgery is one of the primary methods for the removal of colorectal cancers. Various surgeries are performed based on the location of cancer and its spread. Due to many shortcomings of extensively invasive procedures, laparoscopy was invented to visualize cancer perfectly and later remove that tumor. However, some technical difficulties were observed, and the physiological complexity of the tumour site caused this method to fail. Later, the FDA announced the approval of a surgical system operated by a team of specialists. This system has more enhanced precision compared to conventional treatments, showing increased efficacy.

Keywords: Efficacy, Laparoscopy, Local excision, Side effects, Surgical system, TME.

INTRODUCTION

Along with chemo and radiotherapy, surgery is another effective treatment for the removal of colorectal cancer. Surgeries are useful in removing tumors that have invaded into deeper layers or, if detected early, can even completely remove the malignancy. Surgical techniques improved with time to give more efficacy and reduced incision size as larger incisions are associated with greater discomfort. This chapter shows such evolution of surgical systems for the treatment of colorectal cancer.

There are many options for surgical removal of rectal cancers.

TOTAL MESORECTAL EXCISION

TME is a broad term used for surgeries to remove rectal cancer. The procedure involves removal of mesentery near as well as far away from the tumour. It is removed sharply while taking care of the autonomic neural network in the area,

* **Corresponding author Sankha Bhattacharya:** Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

maintaining hemostasis, and the integrity of the mesorectal envelope. It is carried out under the rationale that maximum spread of rectal cancer is not beyond mesentery, and removal of mesentery may help prevent the spread further [1].

Techniques Abdominoperineal Resection

Abdominoperineal Resection involves a midline incision through which the abdominal cavity can be accessed. The lymph nodes in the area are examined to assess the spread of tumours. In ureter, gonadal vessels are pushed upwards, and colon and mesocolon are pulled down. The arteries and bowels are ligated while taking care not to harm any organ during that process. Then the mesentery is dissected, starting from the sides and coming to the middle part of the mesentery. Nerves are pushed to the side. Next, the position of the perineum is ensured. The rectum is cleaned, the anus is closed tightly, and an elliptical cut is given around the anus. The ligaments present before the coccyx are divided and the surgeon, with his finger, pulls down the perineum. The excision starts at the backside, comes to the front from the sides. After the removal of cancer, the ligatures on blood vessels are removed and the layers are sewn [2].

Coloanal Anastomosis

This procedure is important for tumors that are present near the sphincter. This procedure enables a surgeon to successfully remove a tumor without harming the sphincter. This is done for the patient suffering from rectal cancer, which is a distal position and has not yet invaded muscular layers of the sphincter and for whom, anterior resection is not possible. The rectum is cut at a distal angle near the pelvic muscles. The remaining muscles are removed and the diseased area is removed. The ends are sewn to restore connectivity [3].

LOCAL EXCISION

Low anterior resection and abdominal perineal resection are majorly used for the removal of rectal cancers, but they usually come with many risks, such as high mortality and morbidity. Hence, the method for local excision to remove the tumour is gaining an advantage [4].

Transanal Excision

For cancers present lower side, local excision is made transverse to the anus. After anesthesia, the patient is made to sleep on his/her stomach. The buttocks are pushed apart. Pudendal nerves are blocked to reduce pain. A retractor is used to expose the lesion inside the anus. Sutures are placed 1-2 cm away from a tumour and a line marking the dissection site is drawn. The tissues are cut using

electrocautery. The lesion is cut while taking care not to harm the other structures. After removal, the excision is filled with polyglycolic structures and sealed [5].

Transcoccygeal Excision

This approach is used for lesions in the middle or distal portion of the rectum. The patient is administered general anaesthesia and made to lie in a prone position. The buttocks are kept apart for the comfort of the surgeon. The patient is draped and sterilized using iodine solution. A cut is made in the posterior along the middle line near the coccyx and sacrum. As the coccyx lies near to the skin, to reach it, the layers such as ligaments are cut from the side and posterior end of the coccyx. The coccyx is pushed to the side and cut from the anterior side till cauterizing wire passes through a sacral coccygeal joint. The coccyx is removed and any bleeding from the sacral artery is controlled using electrocauterizing. Levator muscles and a fat layer are moved to reach the rectum [6].

For posterior tumors, the distal portion of tumour can be felt using fingers. After that, the rectum and mesorectum are cut transversally by 1-1.5 cm away from the tumour. For posterior tumours, this method allows the removal of perirectal nodes. For lesions in the front side, the rectum is cut from the posterior side, and the lesion is exposed clearly. The perianal fat along with the lesion is separated by a radius of 1-1.5 cm around the lesion [6].

Transsphincteric Excision

It involves dissection of the sphincter as well as posterior rectal wall. It is similar to transcoccygeal excision except that now the levator ani and sphincter muscles are divided along the midline. These muscles are re-positioned carefully so they can be sewn back at the end of the procedure. Care has to be taken to not damage the nerve supply to the anus and rectum. After the removal of the lesion, the layers are sewn back again [7].

Transanal Endoscopic Microsurgery

This procedure is performed with the help of a special rectoscope. An obturator was placed before the insertion of a microscope. A glass faceplate is used to hold the position for the insertion of a microscope. The scope is inserted and the glass plate is removed. Carbon dioxide is blown into the rectum to distend it. Epinephrine is injected to allow hemostasis. The margin of resection of 1-1.5cm around the lesion is marked and resected along with the fat layer present around the rectum. The wound is sewn using absorbable sutures [8].

lncRNA NLIPMT Inhibitors in Colorectal Cancer Management

Aseem Setia¹, Sankha Bhattacharya^{2*} and Amaiyya Agrawal²

¹ Department of Pharmaceutics, ISF College of Pharmacy GT Road (NH-95), Ghal Kalan, Moga, Punjab 142001, India

² Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Colorectal cancer (CRC) is a disease that is initiated by the interrelation of genetic and environmental factors. Colorectal cancer progresses through the accumulation of genetic and epigenetic changes. This review discusses, in detail, the role of lncRNAs in colorectal cancer, focusing on various signaling pathways involved in colorectal cancer pathogenesis, viz., Wnt/catenin signaling pathway, epidermal growth factor receptor (EGFR)/insulin-like growth factor type I receptor (IGF-IR) signaling pathway (KRAS and phosphatidylinositol-3-kinase (PI3K) pathways), transforming growth factor-beta (TGF- β) signaling pathway, p53 signaling pathway, and the epithelial-mesenchymal transition (EMT) program.

Keywords: Apoptosis, Colorectal cancer, LncRNAs, Signalling pathway.

INTRODUCTION

Cancer is the abnormal growth of cells that can affect any portion of the body. The rapid formation of abnormal cells is the defining feature of cancer, and then it enters adjoining parts of the body and escalates to other organs; the last process is stated as metastasizing [1]. Cancer metastases are the leading cause of death [2]. According to the report of the World Health Organization (WHO), in 2018, around 9.6 million deaths were estimated worldwide, and 7.6 million deaths were estimated in 2008 from cancer [3]. Some common types of cancer found in males are lung, prostate, colorectal stomach, and liver cancer [4]. Breast cancer, colorectal cancer, lung cancer, cervical cancer, and thyroid cancer are some of the most common types of cancer in women [5]. Changing one's lifestyle and adopting healthier habits could prevent nearly 30% of cancer deaths [6]. Based on

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

the report of the International Agency for Research on Cancer (IARC) published on September 12th, 2018 in “A Cancer Journal for Clinicians,” it has been shown that the top three types of cancer found in human are lung [7], female breast, and colorectal (Table 1).

Table 1. lncRNAs in the blood of cancer patients have been found to circulate.

| lncRNA | Associated Cancer |
|--|---|
| RP11-04K16.1, LOC_012542, PVT1 SNHG1, RMRP H19 PCA3, BCAR4, CRNDE-h, LNCV6_116109, LNCV6_98390, LNCV6_38772, LNCV_108266, LNCV6_84003, LNCV6_98602, u50535 H19, lncUEGC1 LINC00161 | Cervical Cancer Lung Multiple myeloma Colorectal Gastric Hepatocellular carcinoma |

Cancers of the lung and breast account for the majority of cases globally; in 2018, an estimated 2.1 million people were diagnosed with these diseases. Second, in terms of several instances, colorectal cancer has 1.8 million cases and is 10.2% of all cancers diagnosed; prostate has 1.3 million cases and is 7.1%; and stomach cancer is fifth in terms of the number of cases (1.0 million cases, 5.7 percent) [7]. It has been estimated that around 1.2 million patients are diagnosed every year with colorectal cancer [8] (Hermann Brenner *et al.*).

As a multifactorial illness, colorectal cancer (CRC) may be divided into several subtypes based on the relative weight given to each of these risk factors [9]. Only a very small percentage of CRCs are caused by hereditary types of the disease, which accounts for 70% to 80% of cases (Binefa G *et al.* Colorectal cancer prevention and treatment) [10]. The accumulation of genetic and epigenetic alterations is how colorectal cancer grows (Fig. (1)). Adenoma-carcinoma transition period is around 10-15 years, which indicates the time available to discover and remove these adenomas before they become invasive carcinomas [11]. Carcinogenesis of colorectal cancer (CRC) is now being debated in three primary ways [12].




Fig. 1. Onset of Colorectal Cancer.

The first route is known as the “pathway of chromosomal instability” [13]. This path involves the accumulation of mutations that activate oncogenes (KRAS) and inactivate suppressor genes (DCC, APC, SMAD4, TP53) [14]. DNA replication mistakes accumulate owing to mutations in genes that are responsible for correcting them (MSH 2,6,3, MLH 1,3, PMS 1,2, and Exo1) [15] and third route known as “aberrant hypermethylation, a mechanism to silence gene function”. The CpG island methylator phenotype (CIMP) refers to dinucleotide methylation in numerous gene promoter regions [16]. The CIMP accounts for 15%-20% of sporadic CRC [17]. CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 are all considered CIMP-positive indicators if they are methylated [18]. Nearly two-thirds (60%) of all instances of colon cancer occur in industrialized nations, with the highest incidence in Japan. In part, this low death rate can be attributed to the implementation of a screening programme in 1992 [19] (Table 2), one of the first in the world, along with Italy and Israel. CRC is the third most common disease in Europe and is the main cause of deaths due to cancer in the country [20].

Table 2. Colorectal cancer screening programs across the world have a variety of characteristics. FOBT: Fecal occult blood test; FS: Flexible Sigmoidoscopy; CS: Colonoscopy.

| Country | Test | Periodicity | Target Population (age) | Year |
|---------|------------|---------------------|-------------------------|------|
| Germany | FOBT | Annual | 50-54 | 1971 |
| | FOBT or CS | Biennial/Every 10yr | ≥ 55 | |
| Italy | FOBT | Biennial | 50-69/74 | 1982 |
| | FS | Once-only | 58-60 | |

Pathways in Colorectal Cancer

Ajay Madrewar^{1,*}, Kapil Gore¹ and Sankha Bhattacharya¹

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Signaling pathways are important tools for regulating cellular life cycles such as growth and replication. Any external influences may cause a disturbance in signaling, causing an uncontrolled division of cells causing cancer. Many receptors such as EGFR are active in signaling for cancer, which can be targeted to show potent anticancer activity.

Keywords: Chromosomal instability, Microsatellite instability, Pathways, Signalling.

INTRODUCTION

Signaling pathways are important in long-term cellular activities such as the growth and development of cells. Many hormones are involved in such growth, which regulates the various intracellular process. Any disturbances in these pathways may cause disturbances in related processes, which may lead to malignancies [1].

Colorectal cancer is the third most commonly found cancer in men and the second most common cancer in women. It is caused by various genetic and epigenetic alterations, which cause the generation of tumours in colorectal cancer. A four-step pathway is suggested by scientists to explain the generation and progression of colorectal carcinoma.

Three principle genetic abnormalities involved in colorectal carcinoma are:

CHROMOSOMAL INSTABILITY PATHWAY

This pathway is also called as adenoma-carcinoma progression pathway. Its progression into the evolution of disease can be easily predicted and shows

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

specific histology. This pathway causes a proto-oncogene K-Ras and inactivates three suppressor genes, namely loss of APC, loss of p53, and loss of heterozygosity for the long arm of chromosome 18 [2].

Adenomatous Polyposis Coli gene and wnt Signaling Pathway

APC gene-associated polyposis includes conditions such as familial adenomatous polyposis, attenuated FAP, Gardner, as well as Turcot syndrome. FAP gene causes the development of many pre-cancerous polyps around the age of 20. The polyps may turn into a carcinoma decade later. Attenuated FAP shows fewer polyps, and cancer develops later. Gardner syndrome is associated with soft tissue tumours and osteoma, and Turcot syndrome cause nervous system tumours. APC prevents entry of cell into S-phase from G1- phase. The stem cells do not differentiate and remain in the crypt, which allows them to survive. B-Catenin is important in the Wnt signaling pathway and is degraded by the regular APC gene, hence preventing the survival of cancer cells. In sporadic CRC with wild-type APC gene, hypermethylation or point mutation in promoter region causes the continuation of Wnt pathway. Normally, epithelial cells are shed within a week, but such a mutation causes changes in phenotype and prevents shedding of cells, leading to accumulation. This causes the formation of polyps [3].

TP-53 Mutation

TP-53 gene controls cell cycle and apoptosis and usually undergoes mutations in CRC. P53 protein causes the cell cycle to stop and repairs DNA before replication. If the DNA is not successfully repaired, it causes apoptosis of cells. Inherited or germline mutations in tp53 cause a variety of syndromes such as Li-Fraumeni syndrome, affecting various systems such as neurons and soft tissues [4].

18q Loss of Heterozygosity (LOH)

LOH is the loss of one or both the alleles of a gene. This LOH in 18q is frequently seen in advanced colorectal cancer. The remaining allele is also mutated. This missing part contains DCC (Deleted in Colorectal Cancer) gene coding for a similar protein which prevents cell division even in the absence of a ligand. Cells deep in crypts of the colon produce netrin-1 which then declines due to binding to the DCC receptor. This decreasing netrin-1 concentration is essential for the apoptosis of cells. When the DCC gene undergoes mutation, due to the absence of the DCC receptor, the netrin-1 gradient does not reduce and apoptosis is arrested causing continuous growth. Netrin-1 can be overexpressed which resists the apoptosis by DCC [5].

MICROSATELLITE INSTABILITY PATHWAY

DNA nucleotides may be altered by environmental mutagens and errors. During replication, the DNA polymerase enzyme 'reads' one strand to attach the complementary base pairs. But the DNA polymerase enzyme is not always accurate and errors can happen. As the enzyme reads in a 5' to 3' direction, it keeps checking back for errors. If any mistake is found, the enzyme moves back to the position, uses its ability to cleave that base. This function does not always give accurate results. Hence, another system, the mismatch repair system checks and corrects the pairing. Microsatellite instability is seen majorly in Lynch syndrome characterized by an increased probability of cancers of linings such as epithelium, endometrium, skin, brain.

Short tandem repeats (STRs)/microsatellites are small DNA segments containing mono-, di-, tri-, and tetra-nucleotides repeated hundreds of times. These are frequently found in humans. The STRs found in humans are mostly dinucleotide repeats. The microsatellites are alleles in genomes always present in two copies. During replication, a stutter in enzyme may occur which is seen more in the area of these microsatellites. MMR enzymes try to correct this phenomenon by proofreading the microsatellites which preserve the genetic integrity of the human genome. A defective MMR system will leave the genome with shorter or longer microsatellites, which is called microsatellite instability. Inactivation of MMR enzyme may happen due to sudden methylation of promoter gene or point mutations at MMR family. Microsatellite high (MSI-H) is a condition of instability in more than 30% of the markers. Patients with a minor loss of MMR capacity may develop CRC later till the age of 40. In sporadic CRC, the majority of defects are due to hypermethylation of promoters which prevent their expression. As both the alleles are not lost, the MMR function is present but it is chaotic.

MSI tumours are generally seen at the proximal side of the colon and show a cellular structure similar to mucinous carcinoma. It also shows WBC infiltration similar to Crohn's disease [6, 7].

MMR system is effective in correcting the effect of some chemotherapeutic agents, hence granting chemoresistance to malignant cells. MMR also recognizes complexes made in DNA by drugs such as cisplatin, oxiplatin, and 5-fluorouracil hence even after treatment, the prognosis is not altered.

EPIGENETIC INSTABILITY AND CPG METHYLATION

Many mechanisms are responsible for the regulation of DNA expression without a change in nucleotide sequence. Mutations in the promoter region due to sudden methylation may cause changes in epigenetic regulation. Many a time, patients

Radiotherapy in Colorectal Cancer

Amit Page¹, Dnyanesh Saindane² and Sankha Bhattacharya^{2,*}

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Radiotherapy has become an integral part of the treatment of colorectal cancer. Radiotherapy is used as adjuvant therapy in combination with chemotherapy or surgery. In the article, various types of radiotherapy are explained and also the factors involved in the selection of radiotherapy. There have been many clinical trials for investigating the efficacy of various novel radiotherapies, which may show some promising results. Radiotherapy can be adjuvant or neoadjuvant in the combination of first-line therapy to increase the overall effectiveness of the treatment

Keywords: Colon, Radiotherapy, Rectum.

INTRODUCTION

As per the data, in 2018, about 1.7-1.9 billion people have been diagnosed with colorectal cancer, and the deaths reported are close to 900000 [1]. Colorectal cancer is considered one of the common forms of cancer worldwide, with some reports suggesting it as the third most commonly occurring cancer. The most affected countries include Australia, North America, European countries, and New Zealand. Generally, for colorectal cancer, a combination therapy approach is employed, which may include chemotherapy, surgery, and radiotherapy [2]. Radiotherapy is the mainstay of the treatment, whereas chemotherapy and surgery can be used in combination. Radiotherapy, as the name suggests, is a radiation treatment that generally uses higher doses of radiation to kill tumor cells and then shrink them. Also, at lower doses, these radiations are used in X-rays as a diagnostic tool to look inside the body [3]. At higher doses, these radiations kill tumour cells or slow down the progression of a tumour by damaging the DNA. So, when these tumour cells are damaged, the phenomenon is irreversible and becomes non-repairable. When these damaged cells undergo apoptosis, they are discarded by the body. Radiotherapy is not an immediate process and cell death

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

takes more time. Generally, days to weeks are needed after the DNA is damaged to total cell death. The cell death process then continues as radiation therapy is continued [4].

TYPES OF RADIATION THERAPY

Radiation therapy can be classified into two types which is:

External beam radiotherapy (EBRT) and

Internal radiotherapy (brachytherapy) [5]

The choice of radiation therapy is based on many of the factors, and some of the factors are listed below:

- The type of cancer
- The relative size of the tumour
- Actual location of the tumour
- Medical history and overall health of a patient
- Contraindication and allergy scenario
- Other factors like age, gender, patient preference

The role of radiation pharmacotherapy in locally advanced rectal cancers has been steadily changed over the last 3 decades. It emerged in the '80s with a prevalent adjuvant function due to its ability to decrease pelvic recurrence after surgical resection and increase survival rates in combination with 5-FU-based chemotherapy [6]. In the early 1990s, radiotherapy was questioned, with the induction of total mesorectal excision (TME) that significantly reduced locoregional recurrence (LRR) [7]. Several randomized short-term studies (5 Gy X 5 days) have shown the significance of preoperative radiation therapy plus TME in reducing LRR in patients with stage II and III rectal cancer [8]. According to the American Cancer Society, treating colorectal cancer with chemotherapy and radiotherapy simultaneously could make the radiation therapy work better, and when both these treatment strategies are combined, it is called chemoradiation [9].

Radiotherapy is not commonly used to treat colon cancer, but instead, it is used as an adjuvant with other treatment therapies like before surgery along with chemotherapy, after surgery to fully eradicate the tumour if any of the tumour is left or the surgeon is not sure. If a person is not healthy enough for surgery, radiotherapy can be used in combination with chemotherapy. But conversely, radiation therapy is more commonly used in rectal cancers with or without combination [10].

As stated earlier, there are two types of radiotherapies – EBRT and brachytherapy and both these strategies could be used in treating colon and rectal cancer. The type of radiation therapy most commonly used by people with colon or rectal cancer is EBRT. From a computer-based machine outside the body, the radiation is concentrated on cancer. It is a lot like having an x-ray, but this radiation is more powerful. How often and how long a person receives radiation treatment depends on the reason for the radiation and other variables being given. The treatment may last from a few days to a few weeks [11]. New EBRT methods have been shown to help doctors treat colorectal cancers that have spread to the lungs or liver more effectively while minimizing radiation exposure to surrounding healthy tissues, such as three-dimensional conformal radiation therapy (3D-CRT), strength modulated radiation therapy (IMRT), and stereotactic body radiation therapy (SBRT) [12]. All these methods are used only if the number of tumours is very less and where surgery is not possible. Internal radiation therapy is not used commonly as EBRT but it might be used to treat some rectal cancer. Although, it is not used commonly more research is needed in this area. A radioactive source is inserted inside your rectum next to or into the tumour in internal radiotherapy. This helps the radiation to enter the rectum without going through the belly (abdomen) skin and other tissues, so it is less likely to damage surrounding tissues [13].

CLINICAL TRIALS OR RESEARCH STUDIES OF RADIATION AND CHEMO-RADIATION THERAPY IN COLORECTAL CANCER

| Sr.no | Name of the Study | Clinical Conditions | Drug Used and Type of Radiation Therapy | Outcome | References |
|-------|---|---|--|--|------------|
| 1. | AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer | Colorectal cancer, Colorectal Neoplasms, Colorectal Carcinoma | Dug used – AMP-224 & Cyclophosphamide. Radiation– Stereotactic body radiation therapy. | Combination of AMP-224 and low dose cyclophosphamide with stereotactic body radiation therapy (SBRT) was well tolerated but no clinical significance was found in metastatic colorectal cancer patients. | [14] |

Surveillance for Colorectal Cancer

Saurabh Maru¹, Kapil Gore¹ and Sankha Bhattacharya^{1,*}

¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: The incidence of colorectal cancer is very high, and emphasizing the mortality rate of CRC, good screening and surveillance methods are essential for the effective treatment of cancer. Early detection of the CRC is the key for its treatment. If not detected early, it can cause serious symptoms like bleeding and difficulty in bowel movement, which are considered serious symptoms. Different screening procedures are available for the screening and detection of cancer, but the most commonly used technique is colonoscopy, and another less common technique is flexible sigmoidoscopy. People who have a screening colonoscopy have a cancer mortality rate of 68 percent to 88 percent lower. Flexible sigmoidoscopy, although used in many cases has certain limitations, and therefore, colonoscopy outplays it.

Keywords: Colonoscopy, Flexible sigmoidoscopy, Surveillance.

INTRODUCTION

The third most common non-skin cancer is colorectal cancer, affecting men and women of all ethnic groups [1]. Every year, around 150,000 individuals are diagnosed with colorectal cancer, and more than 50,000 die; the lifetime risk is 1 in 23 (4.4%) for men and 1 in 25 (4.1%) for women. When there is a personal or family history of colorectal cancer, an increased risk of developing colorectal cancer is present. One's risk of developing colorectal cancer is often increased by a personal history of breast, uterine, or ovarian cancer. In its early phases, colorectal cancer rarely causes symptoms [2]. Colon cancer typically begins as a harmless or benign polyp. Polyps in the colon may be cancerous or non-cancerous. Screening tests can detect polyps, which can then be removed, preventing the development of colorectal cancer. In up to 90% of cases, early cancers can be healed with surgery. Typically, when colorectal cancer causes bleeding, changes in bowel behavior, or abdominal pain, it progress to a more advanced stage, where less than 50% of patients are healed [3].

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

There are several screening options to consider for physicians and patients today, including colonoscopy, flexible sigmoidoscopy, CT colonography (CTC), and stool tests. Other non-general screening tests are also performed, which include virtual colonoscopy and an enema x-ray test. After inserting air in the colon, a virtual colonoscopy is done *via* a CT scan. Air-filled colon images are transformed into images that look like a colonoscopy. If anomalies are detected, a colonoscopy is required. In patients that have an incomplete colonoscopy, it is also helpful. An air-contrast barium enema is an x-ray procedure that involves filling the colon with air and dye to expose the lining. It is often used only if it is not possible to do a full colonoscopy [4].

In addition to expanded screening efforts, recent studies illustrate promising reductions in CRC incidence and mortality. Since gastroenterologists are the predominant and most efficient providers of colonoscopy in the United States, colonoscopy is both the dominant existing form of screening and an important element in the chain of events that leads to adenoma and cancer diagnosis and resection when other screening modality results are positive. In recent years, studies have shed light on the efficacy of CRC screening modalities and addressed long-standing concerns while also igniting new debates [5].

COLONOSCOPY

Since the 1990s, colonoscopy has become the most popular CRC screening procedure in the United States [6]. Numerous factors have led to this situation: colonoscopy allows for clear visualization of the entire colon, polypectomy may stop precancerous polyps from progressing to cancer, and clinicians may assess reasonable surveillance intervals based on the results of the index test [7]. Colonoscopy has benefits over other screening modalities, such as shorter intervals between tests and improved acceptability and tolerability of current sedation techniques. Despite its widespread availability, it is not considered inexpensive or readily accessible to the general public, making its use in mass screening difficult [8]. Multiple case-control and prospective cohort studies have shown that people who have a screening colonoscopy have a 68 percent to 88 percent lower cancer mortality rate than those who do not. A meta-analysis of retrospective studies found that, despite a 68 percent reduction in overall mortality, colonoscopy had little advantage in terms of cancer in the proximal colon [9]. Another study observed a 29% reduction in overall CRC mortality, a 47% reduction in mortality from distal CRC, and no reduction in mortality from proximal CRC. The above studies show that there is a significant reduction in the overall mortality rate, but these do not apply to all the areas, and there remains a lot of differences [10]. This distinction may be due to several factors influencing the consistency of the act itself (for example, an incomplete colonoscopy, the

gastroenterologist's level of training and experience, insufficient bowel preparation, or technical difficulties with polyp removal in the proximal colon) or variations in the biologic characteristics of proximal and distal colorectal cancers [11]. To fully resolve these concerns, evidence from large controlled randomized trials is still unavailable, although they are currently being performed [12]. Technical societies first supported screening colonoscopy in 1997, and Medicare beneficiaries were authorized for it in 2001. Unlike the faecal occult blood test (FOBT) and flexible sigmoidoscopy, which are backed by RCTs, the use of screening colonoscopy is focused on less-reliable indirect evidence from flexible sigmoidoscopy tests, observational studies, and case-control studies [13]. The United States Multi-Society Task Force on colorectal cancer recently revised its 2006 post polypectomy guidelines, taking into account the interim publication of several related studies, the emergence of serrated lesions, and concerns about decreased right-sided disease. Overall, the updated guideline supports the risk-stratification model based on baseline colonoscopy results, which was developed in 2006, and especially upholds the validity of the 10-year surveillance interval recommended in average-risk individuals after a negative screening colonoscopy. Surveillance guidelines for serrated lesions are also adopted, which are based on a risk-stratification approach [14].

FLEXIBLE SIGMOIDOSCOPY

Periodic screening is the most promising approach for lowering the burden of colorectal cancer. Because of the sensitivity of flexible sigmoidoscopy in detecting early cancers and adenomas, it has been widely recommended at three to five-year intervals. For family doctors, this examination is thought to be a cost-effective intervention [15]. Flexible sigmoidoscopy is also used to screen for colorectal cancer regularly. For people at average risk, most organizations recommend screening every three to five years, starting at age 50. Endoscopic maneuvering, colorectal anatomy, and pathologic recognition require extensive training. After 10 to 25 precepted sessions, most doctors report feeling comfortable performing the procedure without supervision [16]. The sigmoidoscope is inserted through the anus and distal rectum, and the scope tip is advanced into the sigmoid colon during the process. The long flexible sigmoidoscope was inserted between 48 and 55 cm deep on average. The sigmoidoscope is believed to be able to detect about 60% of all colorectal cancers [17]. The three- to five-year screening interval recommendation is based in part on estimates that an adenoma will progress to malignancy in seven to ten years. For people of average risk, most organizations recommend starting sigmoidoscopy screening at the age of 50 [18].

Other than its advantages and its effectiveness, flexible sigmoidoscopy also

CHAPTER 10**Recent Theranostics in Treatment of Colorectal Cancer****Shilpa Dawre¹, Ajay Madrewar¹ and Sankha Bhattacharya^{1,*}**¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Colorectal cancer (CRC) is the common form of cancer occurring worldwide, having a high occurrence rate and also high mortality (death) rate. Chemotherapy and conventional approaches to treat CRCs are outdated and newer strategies are required to combat colorectal cancer. Neoadjuvant therapies have also shown some promise but have some major side effects, like building up intrinsic resistance and systemic toxicity problems associated with such therapies. Cancer nanomedicine, a rapidly developing interdisciplinary research field, is one of the new strategies being developed to address these issues. The use of nanoparticles and nanotechnology in cancer medicine has exploded in popularity over the last few decades. This is due to nanoparticles' suitable physical and chemical properties for *in vivo* applications. Cancer nanomedicine has been extensively studied in preclinical and clinical settings for targeted drug delivery and imaging. Nanomedicine, along with the theranostic approach, has been proposed as a novel way to improve CRC diagnosis and treatment.

Keywords: Nano-formulations, Nanoparticles, Prodrugs, Theranostics.

INTRODUCTION

Colorectal cancer is one of the most widely occurring cancers both in males and females. The yearly deaths caused by colorectal cancer account for about 10% worldwide. The overall 5-year survival rate in colorectal cancer is around 65%, with longer period survival in the past decades only modestly increased [1]. Blood in the stools, abdominal discomfort and pain, weight loss, and asthenia are the major indications associated with it. The risk factors in colorectal cancer could be environmental and genetic factors or a combination of both [2]. While genetic factors account for a minority of cases, there is a clear correlation between a positive history and an increased incidence of colorectal cancer. The so-called

* Corresponding author Sankha Bhattacharya: Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

adenoma-carcinoma sequence, a multi-stage mechanism, is the dominant carcinogenic mechanism model for colorectal cancer [3]. Specific series of events are there in the initiation and development of tumors. Three mechanisms tend to be mainly based on CRC-related genetic alterations: chromosomal instability, high microsatellite instability, or CpG island phenotype methylator [4].

The screening and diagnosis of the colorectal cancer population are made with lots of diverse techniques. Faecal checks are employed to check blood in the stool in people who have no symptoms [5]. Immunochemical faecal occult blood test (iFOBT) and guaiac-based faecal occult blood test (gFOBT) are primarily used in screening programs for low-invasive studies [6]. More specificity is ensured by a stool DNA test, which looks for unique DNA mutations. Blood-based screening tests are useful for diagnosis, such as the identification of CEA antigen, the most well-known CRC tumor marker [7]. The FDA has recently approved the use of some novel techniques, such as CellSearch™, to detect circulating tumour cells; however, these techniques are expensive and routinely not easy to implement [8]. Colonoscopy is reserved for symptomatic patients or is used only as a second-line procedure for routine screening of fecal test-positive patients. However, this technique is invasive, has some patient compliance concerns, and has some risks, like using anesthesia and possible cell or organ damage [9]. Alternative methods, such as barium enemas for X-ray rectal outlining or more complete techniques, including virtual colonoscopy and computed tomographic colonography, are available if this method is not feasible, but they involve colon cleaning before the examination and may detect non-neoplastic anomalies [10]. The introduction of nanomedicines is important for the effective treatment of any cancer. Not only in a therapeutic way, but nanomedicines are also used alternatively in a very potential way as a diagnostic tool. When these diagnostics nanomaterials are combined with therapeutics, they offer a very less toxic theranostic pathway [11].

NANOPLATFORMS FOR DRUG DELIVERY AND THERANOSTICS

Various tumour tissues are generally being identified as the cancer of the breast, colon, rectum, prostate, brain, *etc.*, but these all tissues are permeable to nanomedicines and nanoparticles [12]. Nanoparticle and nano-molecule drug delivery mechanisms can be divided into active and passive targeting. Active targeting strongly depends on the interaction between the target cell receptors and nanoparticles, while passive targeting relies on a variety of factors, such as longer biological half-life, long-circulating period at tumour locations, and the flow rate of nanoparticles to the disabled lymphatic system [13]. The EPR effects play a vital role and pose a serious issue for any nanomedicine or nanoformulation, which rapidly increases the uptake of these nanomedicines from the systemic circulation by macrophages, and therefore, the nanoparticles are cleared at a very

rapid rate from the body [14]. Targeted nanoparticles are currently one of the key methods for CRC therapy in preclinical development as a drug delivery mechanism based on monoclonal antibodies. There are different approaches for theranostics, and some are explained below [15].

NANOLIPOSOMAL BASED THERANOSTIC NANOPARTICLES

In 1961 Bangham *et al.* introduced the first therapeutic nano-platform used in medicine. This nano-platform was built on liposomes, which are the nanovesicular carriers and also the first clinical drug delivery system approved by the FDA for clinical use [16]. One of the widely used nanoparticles for the delivery of small peptides, nucleic acids, and proteins in nano-platform drug delivery is liposome-based nanoparticles. At the cellular level, nanoliposomes are known as one of the most powerful drug delivery mechanisms. This is primarily due to their size, ability to incorporate different substances, and characteristics of slow-release and targeting, which often contribute to lesser side effects [17]. Liposomes are now widely used as therapeutic nanocarriers, and they are also used in diagnostic tooling. The use of liposomes for molecular diagnosis is now a widely studied topic; the use of liposomes can be used for the diagnosis of various life-threatening diseases, like cancer, and various nondegenerative diseases, like Alzheimer's, *etc.* The liposomes' work involves the covalent binding of liposomes with peptides, antigens, and antibodies. While the formulation of such specialized liposomes that respond to the external stimuli are also in research progress and are now formulated, showing dormant results in neuro-imaging and diagnostic research [18].

Generally, this liposomal system can be classified into 3 main types:

1. Stealth Liposomes – These are large vesicular carriers and can be unlayered or multi-layered vesicles with some modified structure like added Polyethylene glycol (PEG) and or gangliosides to bypass the RES system by avoiding blood plasma opsonin protein which directly binds to the liposomal surface thereby inhibiting their activity.
2. Active liposomes – These liposomes are used for targeting specific moieties like receptors, proteins, peptides, hormones, antibodies, *etc.*
3. Sensitive liposomes – These are specialized types of liposomes with unique properties and be further subdivided as pH-sensitive, thermo (temperature) sensitive, and magnetic liposomes [19].

An example of an FDA-approved nanoliposome for colorectal chemotherapy is doxorubicin (Doxil[®])-liposome Doxil is around 100 nm, and although it has much less gastrointestinal and cardiac toxicity, other side effects such as redness and

CHAPTER 11**Management of Colorectal Cancer****Sankha Bhattacharya¹, Amit Page¹, Saurabh Maru¹ and Shilpa Dawre¹**¹ Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India

Abstract: Management of colorectal cancer is a very important part of treatment as improper procedures may cause certain complications. Many decisions regarding the treatment depend on the condition of the tumour and the patient, and also the focus is on the treatment to be performed without complications. Management is done by first preparing the patient with different procedures, like stomal therapy, bowel preparation, or nutritional intervention. Then, the tumour is further evaluated, and accordingly, the treatment option is selected. Possible treatment options could be electrocoagulation, touch radiotherapy, local excision with or without neoadjuvant/adjuvant therapy; they all are local treatment methods for rectal cancer and endoscopic treatment. The results may vary with the selection of the procedure and the prognosis.

Keywords: Colorectal cancer, Electrocoagulation, Endoscopic treatment, Local excision, Stomal therapy, Tumour evaluation.

MANAGEMENT OF COLORECTAL CANCER

Kilian G M Brown *et al.*, reported that in high-income countries, the occurrence and mortality rates are higher for colorectal cancer [1]. Primary care physician plays a very vital role in coordinating when the multimodal management strategies are considered for colorectal cancer [2].

For primary confirmation, the endoscopic biopsy is further correlated with histology. Also, at the clinical-stage, identification is important. Primary care physicians can provide some prognosis and management guide. Computed tomography (CT) scan of the pelvis, abdomen, and chest is suggested in the UK and Australia to have better understanding of the disease spread and condition. [3]. The stages are based on the magnitude of regional tumour incursion (T Stage), engagement of lymph nodes (N stage), and distant metastases (M Stage). The past diagnosis reports or imaging can be investigated for under-

* **Corresponding author Sankha Bhattacharya:** Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India; Tel: +917878777207; E-mail: sankhabhatt@gmail.com

standing the metastases with further analysis of patients' blood for electrolytes, blood component count, and renal functioning. For post-treatment analysis, the disease surveillance is carried out with baseline carcinoembryonic antigen (CEA) [4].

A specialist investigation by an oncologist or surgeon would be necessary. The investigation is carried out with an MRI of the liver because detection of IV contrast medium with a CT scan is not possible in some patients. Initiation investigation with a CT scan or MRI is the choice of the patient who has rectal cancer. The use of MRI provides accurate staging investigation [5].

HOW CAN YOU PREPARE PATIENTS FOR SURGERY?

In primary care, many aspects related to preoperative assessment are taken care of. A preoperative optimization process is most often coordinated by colorectal cancer preadmission or preoperative examination clinics. However, this varies by healthcare environment [6].

Enhanced Recovery After Surgery (ERAS)

This consists of the standard care within preoperative management for patients undergoing colorectal operations. Variations can be seen in different institutions in the protocols of ERAS. Early mobilization, anesthetic practice, enteral nourishing, improving preoperative dietary position, education, counseling, and postoperative analgesics are all examples of postoperative management. With these protocols, the patients' stay can be shorten and complications can be reduced [7].

Stomal Therapy

Some patients may or may not require a temporary or permanent stoma after colorectal surgery. Due to some complications that get created due to the stoma like retraction, dermal abrasion, and parastomal herniation. The stoma formation is affected by factors like the stage, size, and location of the tumour; treatment; patient condition, and emergency surgery need. The low or mid rectal tumour may need a short-term ileostomy. This therapy is optional and can be picked up if desired by the patient. However, the stomal therapist needs to examine and also select an appropriate location for stoma [8].

Bowel Preparation

For administration of oral laxative, a solution is being utilized and a clear fluid diet is given preoperatively for at least 24 hours. For colonic resections, this is not much favored by the surgeons. In several studies, it has been indicated that post-

operative infections can be treated with mechanical bowel preparation and antibiotics. Though there is some ambiguity, current UK guidelines warn against frequently adopting mechanical bowel preparation before colorectal cancer resections, so they do note that it can be beneficial in patients undergoing rectal cancer restorative resection [9].

Nutritional Interventions

Malnutrition is common among cancer patients in terms of chemotherapy, radiotherapy, and surgery, as well as the metabolic consequences of cancer. Colorectal cancer patients are at a higher risk of malnutrition than most cancer patients. Patients with rectal cancer who undergo neoadjuvant chemoradiation have the highest rates. Though nutritional evaluation and support are systematically given before colorectal surgery, there is a deficiency of details on its potency. Preoperative carbohydrate loading is often considered in patients experiencing colorectal cancer surgery. On the day of surgery, a smooth, oral carbohydrate solution is delivered before midnight and again 2-3 hours before surgery [10].

LOCAL RECTAL TREATMENT OF RECTAL CANCER (CLINICS IN THE COLON A RECTAL)

Local treatment of rectal cancer remains a hot topic of discussion, with surgeons worried that a narrow approach that avoids a colostomy may decrease the possibility of cure. Despite improvements in surgical practice and the introduction of a multimodality approach to the treatment of rectal cancer that has increased sphincter-preservation rates, abdominal procedure are also associated with some morbidity and mortality. Cardiopulmonary compromise and collapse, anastomotic leakage and strictures, genital and urinary dysfunction, and clinical difficulties with defecation and continence are also complications of radical operations [11].

The lower morbidity associated with local therapy, along with the maintenance of normal bowel function after local excision, makes it a more appealing choice, helping to keep it on the rectal cancer care algorithm as a feasible option in the management of select rectum cancers. Furthermore, as we gain a greater understanding of the clinical behavior of the tumour and the prognostic importance of histologic grading and tumour characteristics, the use of local therapy in the treatment of rectal cancer will grow, ensuring its place as an alternative to radical surgery [12].

Tumor Evaluation

A systematic assessment of the patient is critical in the design of an effective

SUBJECT INDEX

A

Abdominal perineal resection 38
 Abnormal barium enema 12
 Acid, folic 26
 Acids 29, 97
 nucleic 97
 phenolic 29
 Action 29, 30, 58
 antiapoptotic 58
 anticancer 29
 downstream 30
 Activity 28, 31, 32, 53, 56, 57, 61, 76, 77, 97,
 106
 antioxidant 28
 lymph node 106
 transcriptional 57
 Adenocarcinomas 18, 19, 21, 84
 mucinous 18
 Adenoma(s) 12, 13, 47, 74, 91, 92
 aggressive 12
 carcinoma 74
 tissue 13
 Adjuvant chemotherapy 25, 33, 111
 Aerobic glycolysis 60
 Agents 24, 28, 31, 32, 50, 73, 98, 108
 anti-inflammatory 28
 chemotherapeutic 24, 73
 chromoscopic 108
 mechanistic 50
 theranostic 98
 Age standard rate (ASR) 1
 Air-contrast barium enema 91
 Akt 53, 74, 76, 77
 phosphorylated 74
 signaling 53
 Anaesthesia 39, 42, 107
 Anaesthesiologist 42
 Anastomosis 41
 Anesthesia 38, 96
 Anesthesiologist 42
 Angiogenesis 30, 31, 60, 75
 Anomalies 28, 91, 96

 non-neoplastic 96
 Anthocyanins 29
 Antibodies 24, 29, 30, 32, 74, 97, 100
 chimeric 29
 Anti-EFGR agents 34
 Antigens 4, 5, 33, 97, 99, 104
 baseline carcinoembryonic 104
 carbohydrate 4, 5
 APC 56, 74
 gene 56
 mutations in adenoma-carcinoma 74
 Apoptosis 28, 29, 50, 51, 53, 54, 58, 60, 62,
 72, 74, 75, 76, 77
 Autonomic neural network 37
 Autophosphorylation 75

B

Biocompatible polymer coating 99
 Biomarkers 4, 100
 leveraging tumour 100
 sensitive 4
 Bladder sarcomas 54
 Block cyclooxygenases 28
 Blood 43, 96, 104
 based screening tests 96
 component count 104
 transfusion 43
 Bowel(s) 13, 41, 43, 90, 103, 104, 107, 111
 function 41, 106
 movement 90
 obstruction 111
 planning 107
 post-surgical 43
 preparation 13, 103, 104
 Brachytherapy 82, 83
 Bronchial tumour 5
 Burning sensation 87

C

- Cancer(s) 3, 4, 5, 16, 18, 19, 20, 21, 24, 25, 26, 29, 31, 32, 33, 34, 38, 46, 47, 49, 50, 52, 54, 71, 81, 90, 91, 98, 105, 106
 - antigens (CA) 4, 5
 - bladder 52
 - breast 5, 31, 46, 49, 52
 - cell invasion 49
 - cervical 46
 - gastric 5, 32
 - liver 32, 46
 - lung 31, 46, 54
 - metastases 3, 46
 - metastatic 25, 26
 - oesophageal 52
 - ovarian 52, 90, 98
 - pancreatic 5
 - rectum 105
 - stomach 47
 - therapeutics 98
 - thyroid 46
- Cancer cells 21, 24, 27, 33, 54, 72
 - mesenchymal-like 54
- CAPOX therapy 33
- Carcinogenesis 4, 47, 53, 54, 58, 62
- Carcinoma 9, 10, 11, 12, 13, 16, 19, 20, 31, 47, 50, 51, 52
 - adenosquamous 19
 - hepatocellular 31, 52
 - invasive 47
 - neuroendocrine 19
 - ovarian 51
 - renal 50
- Cell 5, 27, 29, 49, 50, 51, 52, 53, 58, 60, 62, 74, 76, 78, 81
 - cycle repression 58
 - death 27, 29, 49, 60, 78, 81
 - growth arrest 49
 - invasion 62
 - proliferation 5, 29, 50, 51, 52, 53, 60, 62, 74, 76
- Chemoradiation 82, 84, 85
- Chemo-radiation therapy 83
- Chemoresistance 53, 73
- Chemosensitivity of CRC cells 53
- Chemotherapeutic effect 5
- Chemotherapy 24, 25, 26, 29, 34, 81, 82, 85, 86, 87, 100, 105, 111
 - systemic 24, 25
- Chromatin interactions 57
- Chromoendoscopy 109
- Chromosomal instability pathway 48, 71
- Circumferential resection margin (CRM) 42, 43, 86
- Cisplatin resistance 53
- Coloanal anastomosis 38
- Colon 11, 86, 92, 109
 - biopsy 11
 - carcinoma 11
 - malignant 109
 - sigmoid 86, 92
- Colon cancer 28, 34, 48, 50, 82, 90, 98, 110
 - therapy 98
- Colonoscopists 93
- Colonoscopy 2, 3, 10, 11, 12, 13, 46, 48, 63, 83, 90, 91, 96, 104, 105, 109, 110
- Colorectal 4, 10, 47, 50, 59, 63, 84, 92, 97
 - adenocarcinomas 4, 84
 - anatomy 92
 - carcinogenesis and progression 59
 - chemotherapy 97
 - neoplasia 10, 63
 - neoplasms 2, 83, 109
 - metastatic 83
 - stomach 46
 - surgery 104, 105, 110
- Colorectal cancer 31, 61, 62, 84, 105, 111
 - cell migration and invasion 61, 62
 - liver metastases 84
 - resections 105
 - treatment 111
 - metastasizing 31
- Colostomy 105
- Combination of FOBT and Flexible Sigmoidoscopy 11
- Compensatory hyperplasia 27
- Computed tomography (CT) 3, 10, 13, 91, 103, 107
 - colonography 10
 - colonoscopy (CTC) 13, 91
- Computer-based machine 83
- Conduct biopsies 85
- Conventional surgical methods 40
- Corticosteroids 110
- CRC 3, 52, 53, 62, 96, 97
 - diagnosis sigmoidoscopy 3
 - invasion and metastasis 53
 - malignancy 52
 - related genetic alterations 96

Subject Index

therapy 97
tumor 62
CRC treatment 1, 33, 53
 diagnosis improvise 1
 metastatic 33
Crohn's disease 20, 73
CT colonography 13, 91
Cyclooxygenase 28
Cytoplasm 17

D

Damage 28, 39, 42, 43, 83, 107, 109
 reducing radiation 107
Delivery 24, 95, 97, 98
 cancer drug 98
 nano-platform drug 97
 targeted drug 95
Development 50, 52, 54, 76
 embryonal 52
 embryonic 50
 intestinal 76
 microsphere 54
Developmental process of nonpolypoid
 colorectal neoplasms 2
Diarrhoea 27, 111
Dipyrimidine dehydrogenase deficiency 26
Disease 4, 5, 8, 9, 10, 12, 13, 16, 19, 20, 28,
 32, 46, 47, 53, 61, 97, 103, 110
 autoimmune 5
 inflammatory bowel 4, 10
 life-threatening 97
 malignant neoplastic 12
 metastatic 61
 pulmonary 110
Disease-free survival (DFS) 26, 42, 52, 54
DNA 20, 27, 28, 72, 73, 81, 82
 expression 73
 nucleotides 73
 oxidize 28
 polymerase enzyme 73
 repairs 72
 synthesis 27
Double-contrast barium enema (DCBE) 12, 13
Downregulation 52, 62
Downstream 74
Drugs 24, 25, 27, 28, 29, 30, 31, 32, 84, 85,
 86, 98
 anticancer 98
Dyspareunia 111

Colorectal Cancer Diagnosis and Therapeutic Updates 117

Dysplasia 17

E

Efficacy, therapeutic 99
EGFR 55, 75, 76
 IGF-IR signaling pathway 55
 MAPK Signaling Pathway 75
 pathway 75
 signalling pathway 76
Electrocoagulation and endoscopic laser
 treatment 106
Embryogenesis 56
Endogenous sponge 61
Endorectal ultrasonography 3
Endoscopic laser treatment 106
Enzyme 1, 27, 28, 32, 73, 98
 cyclooxygenase 28
 lysosomal 98
 stimulated activation 98
 thymidylate synthase 27
 tyrosine kinase 32
Epidermal growth factor receptor (EGFR) 29,
 30, 46, 52, 59, 60, 63, 71, 74, 75, 76
Epigenetic disorders 2
Epinephrine injection 109
Epithelial 17, 46, 54, 58, 59, 60, 61, 63, 74
 cells, glandular 17
 mesenchymal transition (EMT) 46, 54, 58,
 59, 60, 61, 63, 74
Erectile dysfunction 87, 111
Erythroblastosis oncogene 29
European society of medical oncology
 (ESMO) 86

F

Faecal occult blood test (FOBT) 11, 13, 48,
 63, 92, 96
Flexible sigmoidoscopy tests 92
Fluorescence 62, 99
 in situ hybridization 62
 turn-on response 99
Fluoropyrimidine 26, 33
 based therapy 33
Fluorouracil-containing adjuvant 111
 chemotherapy 111
FOLFIRI regimen 29, 31
Foods 28

functional 28
Fructosyl transferase 52
Functions 48, 51
 oncogenic 51
 silence gene 48

G

Gardner syndrome 72
Gas embolism 42
Gastroenterologists 91
Gastrointestinal observations 106
Gene(s) 9, 12, 48, 49, 50, 51, 52, 53, 56, 57, 59, 60, 61, 72, 75, 76, 78, 79, 85
 associated polyposis 72
 downstream 75
 expression 49, 50, 57, 85
 multidrug-resistant 53
 mutations 9
 oncosuppressive 56
 protein-coding 51
 transcription 50
 tumor suppressor 61
Genitourinary functions 41
Genomes 73
Glandular nature 17
Glioblastoma 32
Glucocorticoid response element (GRE) 50, 63
Glycogen synthase kinase 49, 63
Glycoproteins 4, 5
 tumor-associated 5
Growth factor 27, 29, 30, 31, 49, 50, 63, 74, 75, 77
 fibroblast 30
 hepatocyte 31
 hormones 50
 human epidermal 29
 placental 30
 reducing proteins 27
 transforming 49, 63

H

HER2 inhibitor 30
HGF 32
 activator inhibitors (HAIs) 32
 Inhibitors 32
Histopathologic analysis 18

HNPCC adenomas 12
Homeobox transcript antisense intergenic RNA 50, 63
Homeostasis 33, 76
Hydroxypropyl methylcellulose 108
Hypermethylation 61, 72, 73
Hyperplasia 5

I

Imaging 86, 95, 103, 107, 109
 magnetic resonance 107
 narrow-band 109
Immunogenicity 29
Inguinal lymphadenopathy 106
Injections 26, 108, 109
 submucosal fluid 108
Internal radiation therapy 83
International agency for research on cancer (IARC) 47, 63
Invasion 16, 19, 20, 25, 33, 49, 50, 51, 54, 60, 61, 62, 111
 hepatocellular carcinoma 60
 lymphovascular 111
Invasive 19
 cancers 19
 malignancy invades 19

K

Kinases, activating 78
KRAS oncogenes 74

L

Laparoscopic 40, 41, 42, 43, 44, 110
 colectomy 110
 resection 110
 surgery 40, 41, 42, 43, 44, 110
Laparoscopy 37, 40, 41
Lentivirus transfection 62
Lesion 3, 11, 38, 39, 84, 100, 108, 109
 distal colon 11
 invasive 108
 metastatic 100
 neoplastic 108
Li-Fraumeni syndrome 72
Lipid kinases 74
Liposomes 97

Subject Index

magnetic 97
Lipoxygenase 28
Liver metastases 20, 84
LncRNA 51, 55
 and neighboring protein-coding genes 51
 in cytoplasmic functions 55
Loss of heterozygosity (LOH) 72
Low-density lipoprotein 79
Lymphatic drainage 110
Lymph node metastases 50, 54, 106
Lynch syndrome 73
Lysosomal 1, 5, 6
 exoglycosidases 5, 6
 exoglycosides 1

M

Malnutrition 105, 110
MAPK pathway 30, 74, 75, 78
Medical radioisotopes 99
Medullary carcinomas 18, 20
Medulloblastoma 29
Melanoma 29, 30
Mesenchymal 31, 74
 epithelial transition factor 31
 transformation 74
Metastasis 1, 5, 25, 26, 31, 32, 34, 53, 49, 54,
 59, 60, 61, 74, 77
 bladder cancer 61
 combat breast cancer 49
Metastatic colorectal cancer 31, 83
Methods 41, 99
 laparoscopic 41
 molecule-based theranostic 99
Microbial flora 28
Microsatellite instability pathway 73
MMR 73
 enzymes 73
 system 73
Monoclonal antibodies 29, 74, 97
Monotherapy 31
Morphogenesis 31
Mortality 6, 9, 11, 12, 63, 91, 105, 107, 110
 reduced 9
 reducing 11
MRI contrast agents 99
MTX-resistant CRC 53
Mucin 18, 20
 extracellular 20
Mucinous 19, 20, 73

Colorectal Cancer Diagnosis and Therapeutic Updates 119

carcinomas 20, 73
Multifunctional proteins 74
Multistage carcinogenesis in colorectal cancer
 55
Muscles 17, 38, 39
 pelvic 38
Muscularis mucosae 17, 19
Mutations 13, 48, 60, 72, 73, 74, 75, 78
 germline 72
 somatic 74

N

National comprehensive cancer network
 (NCCN) 25
Nausea 27, 111
Necrotic patches 19
Neoadjuvant 33, 86, 93, 95, 105
 chemoradiation 105
 radiation therapy 86
 therapy 33, 86, 93, 95
Neoplasms 2, 5, 11
 advanced proximal 11
 distal colonic 11
Neoplastic colon cells 60
Nerves 38, 43
 sympathetic 43
Neuropathy 27
Neutropenia 27
Non-invasive diagnosis methods 3
Nonpolyposis 20
Notch signaling pathway 75
Nuclear 3, 99
 magnetic resonance (NMR) 3
 medicine applications 99

O

Oncosuppressive protein 56
Overexpression of NLIPMT in CRC cells 62
Oxa chemosensitivity 53

P

Paclitaxel resistance 53
Pain 38, 40, 90, 93, 95
 abdominal 90
Pancreatitis 4

Pathways 20, 30, 31, 32, 54, 55, 60, 71, 72, 74, 75, 76, 77, 78, 79, 96
 adenoma-carcinoma progression 71
 toxic theranostic 96
 ubiquitin-proteasome degradation 77
 Peptides, antioxidant 28
 Peritonitis 109
 PET/CT tomography 3
 Peutz-Jeghers syndrome 10
 Phosphorylated tyrosine 75
 PI3K 60, 77
 AKT signalling pathways 60
 Signalling Pathway 77
 Polypectomy 19, 91
 Polyps 3, 9, 10, 11, 12, 17, 25, 59, 72, 90
 amputation of 11, 12
 pre-cancerous 72
 Positron emission tomography 3
 Post-alcoholic hepatitis 5
 Prognosis 4, 18, 19, 22, 57, 62, 73, 74, 103, 109, 112
 histopathological analysis 18
 Prostate biomarker 100
 Protein(s) 27, 30, 54, 55, 56, 60, 63, 72, 74, 75, 76, 77, 78, 79, 97
 activated 77
 phosphatase 63
 receptor-related 79
 Protein kinase 74, 77
 mitogen-activated 74
 Protooncogene 30

Q

QRT-PCR and survival analysis 62

R

Radiation therapy 82, 83, 84, 85, 86
 in metastatic colorectal cancer 83
 stereotactic body 83, 84
 three-dimensional conformal 83
 Radio-chemotherapy 3
 Radiotherapy 37, 81, 82, 83, 84, 85, 86, 87, 105
 neoadjuvant 85
 RASMAPK signaling pathway 53
 RAS pathway 30, 74
 Reactive oxygen species 28

Rectal cancer 85, 105
 care algorithm 105
 metastatic 85
 Regulation, epigenetic 50, 73
 Resection 104, 107, 110, 111
 colonic 104
 oncologic 107
 radical 107, 110
 rectal 110
 syndrome 111
 RES system by avoiding blood plasma
 opsonin protein 97
 RNA immunoprecipitation 62
 Role of adjuvant chemotherapy 111

S

Screening 10, 13, 90, 91, 92
 colonoscopy 13, 90, 91, 92
 techniques 10
 Secretion, immunosuppressive factors 33
 Sensitive liposomes 97
 Sigmoid colon 86
 cancer 86
 organ motion in radiotherapy 86
 Sigmoidoscope 92
 long flexible 92
 Sigmoidoscopy 2, 3, 8, 10, 11, 12, 92, 93
 flexible fiberoptic 93
 screening 11, 92
 Signaling 29, 49, 55, 71, 74, 77, 78
 downstream 74
 intracellular 29
 oncogenic 74
 Signal-regulated kinases 75
 Signal transducer protein 74
 Skin 39, 73, 78, 83, 86, 98
 itchy 86
 irritation 86
 peeling 98
 redness 86
 Smad-independent signalling 60
 SMAD 77
 proteins 77
 signaling 77
 Snare polypectomy 108
 Sphincter consistency 106
 SPION 99
 formulations 99
 medications 99

Subject Index

Stereotactic body radiation therapy (SBRT)
83, 84
Stereotactic radiotherapy 84
Stress-activated kinases 75
Submucosal cushion 108
Super magnetic iron-oxide nanoparticles 99
Survival 9, 26, 29, 31, 33, 42, 52, 54, 60, 72,
75, 109, 111
disease-free 42, 52, 54
progress-free 26
progression-free 29, 31, 33
Syndromes 12. 72
genetic 12
System 19, 21, 29, 33, 37, 42, 43, 72, 73, 96,
97, 100
disabled lymphatic 96
high-performance vision 42
immune 29, 33
liposomal 97
mismatch repair 73
Systemic toxicity problems 95

T

Target tumor suppressor 54
Techniques 3, 6, 13, 37, 44, 90, 93, 96
invasive 6
mastered endoscopic 93
non-invasive 6
novel 13, 96
surgical 37, 44
Tensin homolog protein 77
Tests 3, 4, 8, 10, 11, 12, 13, 48, 63, 91, 92
epigenetic 4
faecal occult blood 13, 92
fecal occult blood 3, 8, 10, 48, 63
Theranostic prodrug approach for colon
cancer therapy 98
Therapy 24, 25, 30, 33, 49, 79, 81, 84, 85, 86,
87, 95, 99, 100, 104
adjuvant 33, 81, 87, 100
conventional surgical 86
targeted HER-2 30
targeted photothermal 99
Thymidine phosphatase (TP) 5
Thymidylate synthase 27
Tissues 16, 17, 25, 38, 83, 96, 100
adipose 17
murine colorectal cancer 50
Tomographic colonography, computed 96

Colorectal Cancer Diagnosis and Therapeutic Updates 121

Tomography, computed 3, 103
Transanal endoscopic microsurgery 39
Transcript 51, 54, 63
nuclear-enriched 54
Transcription 27, 51, 55, 60
nuclear 55
Transcription factors 57, 60
Transition 46, 54, 56, 60, 63
epithelial-mesenchymal 46, 54, 60, 63
Transmembrane 60, 75
proteins 75
serinethreonine kinase receptors 60
Tumor(s) 4, 5, 17, 18, 25, 27, 31, 32, 33, 37,
38, 49, 50, 51, 55, 74, 75, 85, 86, 106,
107
gastrointestinal 5
intestinal 4
malignant 55
neoplastic 17
suppressor 49, 50
Turcot syndrome 72
Tyrosine kinase inhibitors 31

U

Upstream signaling inhibitor 30
Urinary 87, 105
bladder irritation 87
dysfunction 105

V

Vascular endothelial growth factor 30
Vomiting 27, 111

W

Warburg effect 60
Wnt signalling 56
World health organization (WHO) 9, 21, 46

Z

Zinc finger protein 57

Sankha Bhattacharya



Dr. Sankha Bhattacharya did his Post Doctorate from the Indian Institute of Technology (BHU), Varanasi, INDIA (August 2018-August 2019) in cancer nanomedicine and molecular pharmacology. He did his Ph.D. from the School of Pharmacy, RK University, Rajkot, INDIA (June 2014-April 2018). He is currently serving as an Associate Professor in the Department of Pharmaceutics, School of Pharmacy & Technology Management Shirpur, NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India, with 11.3 years of Research and Teaching experience. He has published more than 25 national and 41 international papers in high-impact factor and peer-reviewed journals. In 2016, he was awarded Minor Research Fellow (MRF) from Gujarat Council on Science and Technology (GUJCOST /MRP/2015-16/2677) for his contribution to cancer research.

Amit Page



Dr. Amit Page did Ph. D (2015) from SVKM's NMIMS, on the topic Angiogenesis and its Modification in Developing Therapeutic Agents. He pursued his graduation in Pharmacy (1998) and Post-Graduation (2002) in Biopharmaceutics from Shivaji University, Kolhapur, India. He is currently serving as an Assistant Professor in the Department of Pharmaceutics, School of Pharmacy & Technology Management Shirpur, NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India, with about 19 years of Teaching and Research experience. He has six publications to his credit, along with one book on Biopharmaceutics and three book chapters on the global platform. He has been a resource person for community Pharmacists on behalf of pharmacy Council of India, Maharashtra State.

Saurabh Maru



Saurabh Maru (B.Pharm., M.Pharm. -Pharmacology) is a Researcher and Academician, working as Assistant Professor at SPTM, NMIMS Deemed-to-be University, Shirpur, Maharashtra, with 16.5 years of research and teaching experience. He is serving as Associate Faculty of IITB. He served as resource person and advisor at NITI Ayog, AYUSH Dept., MPCST, State NITI & Planning Commission, M.P.; MDRU (DHR, GoI); RRCAT (DAE, GoI) etc. He received awards from organizations like IUPHAR, USA & IPS, NITIE (UN & GoI), DAE-BRNS, IITB, SAS Pvt. Ltd., IACR, IPA, IPC, APTI. He has MoUs as PI and three industry and one internationally funded project. He has 13 publications, 2 international patents, 5 Indian patent applications, 2 book chapters. He is Founder of a socio-scientific initiative NIROG Facilitator Network working for remotely residing tribal people, facilitated more than 4 lakh patients at government hospitals and for government policies.

Shilpa Dawre



Dr. Shilpa Dawre did her Ph.D (Tech) and M.Pharm from Institute of Chemical Technology, Mumbai (India) in Pharmaceutics. She did her Graduation (Pharmacy) from Shri Govindram Sekseriya Institute of Science and Technology with first class. She is currently working as an Assistant Professor in the Department of Pharmaceutics, School of Pharmacy & Technology Management, Shirpur, NMIMS, Shirpur, Maharashtra 425405, India, with 11 years of Research and Industrial experience. She is an author of many national/ international papers and two book chapters on the global platform. She had published two patents (01 international and 01 national). She is award winner of Biotechnology Entrepreneurship Student Team- Association of Biotechnology Led Enterprises 2017, organized by the Department of Biotechnology (DBT), India. She is the receipt of fellowships and fundings from government bodies like the UGC-SAP, DBT, and Indian ICMR,GOI.